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ABSTRACT 
Background 
Atherosclerosis is a modern world scourge and the number of people worldwide diagnosed with type 
2 diabetes (T2D) is on the rise, causing much morbidity and mortality. Endothelial dysfunction (ED) 
is an early sign of atherosclerosis and contributes to vascular complications in T2D. Endothelin-1 (ET-
1) and arginase are two potent inhibitors of endothelium-derived nitric oxide (NO) and are known to 
cause ED. Short term studies have shown that blocking ET-1 can improve ED in T2D but no longer 
term studies have been performed. In addition, it remains unclear which ET receptor subtypes are 
beneficial to block.
Arginase is an enzyme that causes ED and oxidative stress by metabolizing the NO substrate L-arginine. 
The role of arginase in human atherosclerosis and its regulation by ET-1 is unknown. The aim of the 
project was to investigate the role of ET-1 for vascular dysfunction in atherosclerosis and T2D, to 
evaluate the efficacy of ET receptor blockade to improve endothelial function as well as investigating 
the possible interaction between ET-1 and arginase in atherosclerosis.  
Materials and methods
In study I we investigated whether treatment with bosentan, an oral ETA/ETB receptor blocker could 
improve endothelial function in patients with T2D and microvascular complications. Endothelial 
function was tested with Endo-PAT (peripheral artery tonometry) and FMD (flow mediated 
vasodilatation). 
In study II, the effect of  selective ETA receptor blockade vs. combined ETA/ETB receptor blockade on 
endothelial function was investigated in patients with coronary artery disease (CAD) and T2D. 
In study III we investigated the extent of endothelial injury by measuring the number of endothelial 
progenitor cells (EPC) in the patients of Study I. The method used to isolate the EPC was flow 
cytometry by staining for cells positive for CD133, CD34 and KDR.  
In study IV the biobank of carotid endarterectomies (BiKE) was used to determine the gene and 
protein expression of ET-1 and arginase in the atherosclerotic plaque, and to investigate the functional 
interaction between ET-1 and arginase activity in endothelial cells and macrophages. 
Results
Study I demonstrated that 4 weeks oral treatment with the dual ETA/ETB receptor blocker bosentan 
improved peripheral microvascular endothelial function in patients with T2D and microalbuminuria.
In study II it was demonstrated that both selective ETA and dual ETA/ETB receptor blockade markedly 
improved endothelial function in patients with CAD and T2D. However, the addition of ETB receptor 
blockade did not improve endothelial function further. 
Among patients with T2D and vascular disease, high plasma levels of ET-1 were associated with a 
higher number of EPC. The recruitment of EPC did not seem to be regulated via ET receptor activation 
since treatment with a dual ETA/ETB receptor blockade did not affect circulating EPC numbers.
Study IV demonstrated co-localization of ET-1 and arginase in human atherosclerotic plaques. ET-1 
stimulated arginase expression and activity in endothelial cells as well as formation of reactive oxygen 
species in macrophages via an arginase-dependent mechanism. 
Conclusion
Longer term treatment with a dual ETA/ETB receptor blocker improves endothelial function which may 
indicate a role in the treatment of microvascular complications of T2D. Both selective ETA and dual 
ETA/ETB receptor blockade improved endothelial function in a first head to head comparison in this 
patient category.
Important interactions exist between the ET-1 pathway and arginase in human atherosclerotic plaques. 
Our data suggest that a part of the effect of ET-1 on NO and ROS production is through upregulation 
of arginase. 
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SAMMANFATTNING
Bakgrund 
Atherosklerossjukdom och komplikationer till den utgör de vanligaste orsakerna till död och antalet 
människor med typ 2 diabetes (T2D) ökar ständigt och orsakar en enorm börda av mortalitet och 
lidande. Ett förstadium till ateroskleros är endoteldysfunktion (ED) som bidrar till de vaskulära 
komplikationer som orsakas av T2D. Endothelin-1 (ET-1) och arginas är två kraftfulla hämmare 
av produktionen av kväveoxid (NO) i endotelet och bidrar därigenom till ED. Korttidsstudier har 
påvisat att blockad av ET-1 förbättrar ED hos patienter med T2D men långtidsstudier saknas och det 
är fortfarande oklart vilka av ET-1 receptorerna som ska hämmas. Arginas är ett enzym som bidrar till 
ED och oxidativ stress genom att metabolisera L-arginin, substratet till NO-produktion. Betydelsen av 
arginas vid ateroskleros och dess reglering av ET-1 är okända. Syftet med projektet var att undersöka 
vilken betydelse ET-1 har i uppkomsten av vaskulär dysfunktion i ateroskleros och T2D samt att 
utvärdera vilken typ av ET-1 receptorblockad som har bäst effekt på endotelfunktionen. Dessutom 
avsågs att belysa sambandet mellan arginas och ET-1 vid arteroskleros.  
Material och metoder 
I delarbete I undersöktes om den oselektiva ETA/ETB-receptorblockeraren bosentan förbättrade 
endotelfunktionen hos patienter med T2D och mikrovaskulära komplikationer. Endotelfunktionen 
testades med hjälp av Endo-PAT (peripheral artery tonometry) och FMD (flow-mediated vasodilatation). 
I delarbete II jämfördes effekten av selektiv ETA-receptorblockad eller kombinerad ETA/ETB-
receptorblockad på endotelfunktion hos patienter med koronarsjukdom (CAD) och T2D. 
I delarbete III studerades antalet endoteliala progenitorceller (EPC) som en surrogatmarkör för 
kärlskada i studiepatienterna från delarbete I med flödescytometri.
I delarbete IV bestämdes gen- och proteinuttryck av ET-1 och arginas i aterosklerotiska plack från 
halspulsådern i Biobank of Karolinska Endarterectomies (BiKE). Dessutom undersöktes funktionella 
interaktionen mellan ET-1 och arginas i endotelceller och makrofager.  
Resultat
Delarbete I demonstrerade att fyra veckors behandling med den kombinerade ETA/ETB-
receptorblockeraren bosentan förbättrade den mikrovaskulära endotelfunktionen hos patienter med T2D 
och mikroalbuminuri. Däremot förändrades inte endotelfunktionen i ledningsärtär (FMD). I delarbete 
II visades att både selektiv ETA- och kombinerad ETA/ETB-receptorblockad markant förbättrade 
endotelfunktionen hos patienter med koronarsjukdom och T2D. Tillägg av ETB receptorblockad hade 
inte någon ytterligare effekt jämfört med selektiv ETA-receptorblockad.  
Delarbete III visade att hos patienter med T2D och manifest kärlsjukdom, korrelerade höga plasmahalter 
av ET-1 till ökat antal EPC. Rekryteringen av EPC verkar inte vara styrd av ET-1 receptorer eftersom 
behandling med kombinerad ETA/ETB-receptorblockad inte påverkade antalet cirkulerande EPC.
Delarbete IV demonstrerade att ET-1 och arginas är samlokaliserade i endotelceller och makrofager i 
humana aterosklerotiska plack. ET-1 stimulerade arginasexpression och aktivitet i endotelceller samt 
ökar produktionen av fria syreradikaler i makrofager genom en arginasberoende mekanism.  
Konklusion
Fyra veckors behandling med kombinerad ET-1 receptorblockerare förbättrar endotelfunktionen och 
kan eventuellt ha en roll i långtidsbehandling av mikrovaskulära komplikationer vid T2D. Både selektiv 
ETA- och kombinerad ETA/ETB-receptorblockad förbättrade endotelfunktionen markant i en första 
jämförande studie. Det finns en viktig funktionell interaktion mellan ET-1 och arginas i ateroskleros 
vilket kan tyda på ET-1 utövar sin effekt på NO och oxidativ stress via aktivering av arginas.
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INTRODUCTION
Development and clinical consequences of atherosclerosis
Cardiovascular disease due to atherosclerosis is a growing clinical problem throughout the 
entire world. It has an estimated death toll of about 18 million people per year [1]. The number 
of non-fatal cardiovascular events is at least 2-3 times as high. Atherosclerotic disease is 
caused by a constellation of risk factors including hyperlipidemia, hypertension, smoking, 
age and diabetes [2]. These risk factors result in the development of endothelial dysfunction 
which is thought to precede the formation of the atherosclerotic plaque.
The pathophysiology begins with the formation of fatty streaks in the subendothelial layer, 
a process dominated by an influx of macrophages attempting to clear out oxidized LDL 
particles in the intimal layer which results in formation of  a lipid core [3]. Representatives 
of the innate immune system such as macrophages, dendritic cells and monocytes as well 
as the adaptive immune system such as T cells are present in the atherosclerotic core. The 
proliferation and migration of vascular smooth muscle cells leads to the formation of a fibrous 
cap over the core. In addition, both pro- and anti-inflammatory cell types are located within 
the plaque, leading to chronic inflammation which is the prerequisite condition for the plaque 
to develop (Figure 1).
Figure 1. A) Endothelial dysfunction, B) Fatty streak formation, C) Development of an 
advanced complicated atherosclerotic lesion, D) Unstable fibrous plaque in atherosclerosis. 
Reproduced with permission from (scientific reference citation), Copyright Massachusetts 
Medical Society. 
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Later stages involve calcification of the fibrous cap and cell necrosis in the atherosclerotic core. 
This leads to a progressively decreasing lumen of the artery with the development of symptoms 
like angina pectoris and intermittent claudication of the extremities, depending on the anatomical 
location of the plaque. In some cases the plaque is “vulnerable” with a thin fibrous cap prone 
to rupture with increased risk for subsequent sudden thrombosis and acute occlusion of the 
artery leading to myocardial infarction or stroke [2]. The exact cause of the vulnerability is not 
fully clear, although inflammation is thought to be predominant, perhaps steering the cellular 
processes towards scar tissue breakdown and weakening of the fibrous cap [4].
The developmental process of atherosclerosis is thought to take years or decades with 
evidence of early plaque formation in young adults and even fatty streaks present in children. 
The main symptoms of an acute occlusion depend on the location of the afflicted artery. 
Occlusion of a coronary artery results in myocardial ischemia and myocyte necrosis referred 
to as myocardial infarction, the main symptoms of which are chest pain, difficulty breathing, 
nausea and sometimes vomiting. The clinical condition needs urgent treatment with anti-
platelet therapy and percutaneous coronary intervention with balloon angioplasty to restore 
blood flow to the ischemic myocardium. A serious complication of coronary occlusion may 
well be ventricular fibrillation which results in sudden cardiac death.
If the carotid artery is afflicted with thrombosis and embolisation to the brain, the result is 
an ischemic stroke with almost instant neurologic deficits such as loss of movement/motor 
function,  loss of sensation or loss of speech.
Owing to the vast world-wide burden there is still reason to delve into the finer details of the 
atherosclerotic disease process to work out the possible mechanisms and try to prevent or 
stabilize the vulnerable plaque that is the cause of acute cardiovascular events. 
Type 2 diabetes
The prevalence of T2D is an enormous global burden with a doubling of cases since 1980. 
In year 2014, more than 9% of people over the age of 18 were estimated to have T2D [5]. 
Diabetes mellitus is an endocrine disorder characterised by chronically increased levels of 
blood glucose which initiates pathologic processes that have damaging effects on various 
organs [6], most commonly afflicted are the eyes, heart, kidneys as well as the peripheral 
vascular system. T2D is characterized by reduced sensitivity to insulin while type 1 diabetes 
is defined by the inability to produce insulin in the endocrine part of the pancreas. T2D is 
known to be a strong risk factor for atherosclerotic disease with a 2- to 3-fold increased risk 
of myocardial infarction compared to individuals without diabetes. This risk is equivalent 
to the risk of non-diabetic individuals with a prior coronary event [7]. In addition to an 
increased risk of macrovascular complications like myocardial infarction and stroke, the 
condition also causes microvascular complications including nephropathy, retinopathy and 
non-healing foot ulcers [8].
The molecular mechanism by which hyperglycemia causes endothelial dysfunction (ED) as 
an early event in the atherosclerotic process is incompletely understood. However, T2D is 
often accompanied by other cardiovascular risk factors such as hypertension, hyperlipidemia 
and obesity which all have a negative effect on endothelial function [9]. Recent work 
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indicates advanced glycosylated end-products (AGEs) as being central to the damage caused by 
hyperglycemia. AGEs are a heterogenous group of proteins, lipids and nucleic acids that have 
undergone an irreversible glycation and oxidation [10]. Elevated levels of AGEs are thought 
to support the formation of reactive oxygen and nitrogen species, further inducing formation 
of AGEs. In high enough numbers they induce oxidative stress in the mitochondria through 
the receptor for AGEs (RAGE). This then causes mitochondrial dysfunction resulting in cell 
death. These receptors are widely distributed throughout the body as well as being present on 
macrophages. In the macrophage they lead to internalisation of AGEs and subsequent disposal. 
The treatment of T2D is multifactorial. Lifestyle management with physical exercise and 
weight loss together with glucose lowering medication, lipid lowering and antihypertensive 
therapy are needed. Glucose lowering drugs have historically shown little effect on 
cardiovascular complications, although recent additions have had more success [11]. Better 
results have been obtained with statin therapy and drugs lowering blood pressure but still 
diabetic complications cause a staggering amount of morbidity and mortality [12]. In 
light of this there is a need to develop therapies specifically targeting both the micro- and 
macrovascular complications caused by T2D. 
The endothelium
The human artery consists of three distinct layers: Tunica intima, tunica media and tunica ad-
ventitia (Figure 2). Tunica adventitia is the outermost layer and is mostly made from resilient 
connective tissue that maintains structural integrity of the vessel as well as nerve endings and 
small vessels providing nutrients for the artery itself. The tunica media is the muscular layer 
with smooth muscle cells that maintain the vascular tone and modulate blood flow depending 
on the need of recipient organs. The tunica intima is composed of loose connective tissue and 
most importantly the endothelium, the layer of endothelial cells that line the inner wall of the 
artery and are the only cell type that is in contact with blood under normal circumstances [13]. 
Figure 2. Anatomy of the artery on the left hand side, histological section on the right 
hand side, showing the endothelial layer stained in red towards the lumen. Copyright 
Encyclopaedia Britannica, Inc.
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Nitric oxide in endothelial function and dysfunction
Endothelial dysfunction is characterized by reduced bioavailability of NO. Available data 
suggests that it is an important step in the pathogenesis of atherosclerosis and diabetic 
angiopathy due to increased vascular tone, vascular inflammation and oxidative stress [14-
16].  Initially thought to be an inert cell layer, evidence shows that the endothelium acts 
as a transducer and integrator of both humoral and mechanical stimuli [17]. It responds to 
these stimuli by producing different factors that affect nearby cells as well as the endothelial 
cells themselves thereby maintaining the important vascular homeostasis (Figure 3). Nitric 
oxide (NO), discovered in 1980 by Furchgott, Zawadzki and Ignarro [18, 19], is the single 
most important molecule for the healthy homeostasis and reactivity of the vessel. NO is 
produced in the endothelial cells by the enzyme endothelial nitric oxide synthase (eNOS). 
Its production is dependent on the cofactor  tetrahydrobiopterin (BH4) and the availability 
of L-arginine. NO activates guanylyl cyclase in the smooth muscle cells in the vessel wall, 
increasing the formation of cyclic guanosine monophosphate leading to vasodilatation. 
NO is not only vasodilatory but also inhibits thrombocyte aggregation, smooth muscle 
proliferation and leucocyte chemotaxis [16]. It directly interferes with the rolling and 
adhesion of monocytes that would otherwise become macrophages. Its production and release 
is stimulated by a number of physiological stimuli, for example physiological flow forces 
(shear stress), acetylcholine, bradykinin, serotonin, adenosine diphosphate and histamine to 
name a few.
The delicate balance of a normally functioning endothelial layer can be disrupted by 
various factors. The classical risk factors of atherosclerosis like smoking, hypertension, 
diabetes mellitus and hyperlipidemia can disrupt the homeostasis, resulting in an activated/
dysfunctional endothelium [20]. On a cellular level the risk factors decrease the production 
and bioavailability of NO. This decreased bioavailability of NO leads to vasoconstriction, 
increased extravasation of leukocytes and other cells of the immune system as well as 
oxidized LDL particles initiating the formation of an atherosclerotic plaque. Reducing these 
risk factors for endothelial function diminishes the risk of clinical events of atherosclerosis.
Figure 3. Endothelial layer functions.
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Superoxide scavenges the NO molecule leading to decreased bioavailability. Endothelin-1 
(ET-1) and angiotensin II, both potent vasoconstrictors and increased by several risk factors, 
increase the formation of superoxide by activating NADPH oxidase [21]. Another possible 
source of superoxide is eNOS itself, the enzyme that under normal circumstances produces 
NO. This reversal in the function of eNOS happens when levels of the cofactor BH4 is low 
by a mechanism referred to as uncoupling [22]. Also caused by the risk factors mentioned, is 
an increased activity of arginase, which causes a depletion of L-arginine, the substrate needed 
to produce NO, yet another cause of decreased bioavailability of NO. 
The role of ET-1 in endothelial dysfunction and atherosclerosis
One of the factors, potentially contributing to the development of endothelial dysfunction 
in atherosclerosis is overabundance of endothelin, the 21 amino acid peptide. Endothelin is 
a potent vasoconstrictor initially described by Yanagisawa in 1988 [23]. It has three known 
isoforms, ET-1, ET-2 and ET-3, of which ET-1 is the most abundant and relevant in the 
context of atherosclerosis [24]. ET-1 is primarily produced by endothelial cells but also in 
several other cell types in the cardiovascular system. It exerts its effects by activating two 
pharmacologically distinct, G protein-coupled receptors, ETA and ETB. Both receptors are 
present on vascular smooth muscle cells mediating vasoconstriction, while the ETB receptor 
is also present on endothelial cells mediating vasodilatation by releasing NO or prostacyclin 
(Figure 4). ET-1 exerts its effects mostly in a paracrine fashion being secreted from endothe-
lial cells towards the smooth muscle cells of the arterial media [25]. 
Several studies have established that ET-1 has a role in atherosclerosis. ET-1 expression has 
been shown to be increased in animal models of atherosclerotic disease [26, 27]. 
In patients with atherosclerotic disease, administration of the precursor big ET-1 resulted 
in more pronounced forearm vasoconstriction than healthy controls indicating increased 
production of ET-1 [28].
Figure 4. Balance of NO and ET-1 in endothelial and smooth muscle cells. ECE-
1=endothelin converting enzyme-1, ET-1= endothelin 1, ETA=endothelin receptor A, 
ETB= endothelin receptor B, eNOS= endothelial nitric oxide synthase, NO= nitric oxide; 
ONOO−=peroxynitrite, MØ=macrophage. Copyright © 2007, Oxford University Press.
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It is not only that ET-1 is increased as a result of risk factors and early atherosclerosis 
but the relative expression of the receptors is also altered. According to an earlier study, 
expression of the ETB receptor in macrophages and smooth muscle cells was increased in 
atherosclerotic lesions [29]. In an experimental study in patients with atherosclerosis, the 
vasoconstrictive response to ET-1 was not different from that of controls but an ETB receptor 
agonist (sarafotoxin S6c) caused significantly more reduction in forearm blood flow in the 
patients with atherosclerosis, indicating an upregulation of the ETB receptor [30]. However, in 
a mouse model of atherosclerosis there was a 30% reduction in atherosclerotic plaques in the 
group that received a selective ETA receptor blocker [31] but comparison with a dual ETA/ETB 
receptor blocker was regrettably not performed. Collectively, the existing evidence points 
towards a central role of ET-1 in atherosclerotic disease. ET-1 is upregulated in patients with 
risk factors and functional studies show increased response in patients with atherosclerosis 
and its risk factors compared to healthy controls [32-34]. 
The role of ET-1 in type 2 diabetes
The exact pathophysiologic mechanisms behind vascular complications of T2D are not fully 
understood. Most likely a number of different factors contribute to the vascular damage. 
Evidence points towards an enhanced role of ET-1 in this respect.
Elevated plasma levels of ET-1 are found in patients with T2D [35]. Also, increased ET-1 
correlates to impaired glucose uptake, HbA1c levels and the manifestation of microalbuminuria 
and retinopathy [36-38]. In addition, there seems to be an increase in the expression of ET-1 
and both receptors in various animal models of diabetes [39, 40]. Experimental studies have 
shown acute improvement in endothelium-dependent vasodilatation with short-term infusions 
using ET receptor antagonists [41]. In another study, the improvement in endothelium-
dependent vasodilatation in insulin-resistant subjects was achieved using dual ETA/ETB 
receptor blockade whereas no effect was observed following selective ETA receptor blockade. 
This indicates that blocking the ETB receptor may be important to achieve therapeutic 
vascular effects [42] again implying an enhanced role of the ETB receptor in manifest 
endothelial dysfunction. To study the effect of ET-1 regulation on microvascular function in 
T2D patients, the nutritive capillaries in the nail folds were studied. An increase was seen in 
baseline and peak capillary blood velocity after infusion of the ETA receptor blocker BQ123, 
whereas no change was seen in controls [43]. These observations indicate that short-term 
administration of ET receptor blockers acutely improves micro- and macrovascular function 
and may thus be of therapeutic value for patients with T2D. Data regarding the effect of long 
term oral administration of ET receptor blockers on endothelial function are limited. One 
study demonstrated that 6 months treatment with the oral ETA receptor blocker atrasentan 
improved coronary endothelial function in patients with atherosclerosis [44]. However, 
only 2 out of 25 patients included in the active treatment group of that study had diabetes. 
Thus, the effects of oral administration of ET receptor antagonists on patients with T2D with 
manifest vascular complications has not been evaluated.
 
Arginase in atherosclerosis and type 2 diabetes
Arginase is an intracellular enzyme whose activity directly affects NO availability and 
therefore also endothelial function. It is present in two forms; Arginase 1 (Arg1) and Arginase 
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2 (Arg2). Arg1 is primarily found in the liver but is also expressed in other tissues like the 
myocardium, endothelial cells and smooth muscle cells (Figure 5). It is a cytosolic enzyme 
and an important part of the urea cycle in the liver removing excess nitrogen formed during 
amino acid and nucleotide metabolism. Arginase 2 (Arg2) is a mitochondrial enzyme and 
is mostly located in extrahepatic tissues, brain, kidney, small intestine, and immune cells as 
well as in the endothelial cells of  the vasculature [45].
Figure 5. Schematic illustration of the action of arginase in the regulation of NO 
bioavailability and vascular function. Arginase is expressed in endothelial and vascular 
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superoxide and NO will further increase arginase activity and impair NO production via 
oxidation of tetrahydrobiopterin. Collectively, these changes will reduce the bioavailability 
of NO and contribute to endothelial dysfunction. In vascular smooth muscle cells, ornithine 
will increase formation of l-proline and polyamines which stimulate cell proliferation. 
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The role of arginase is thought to be an important key to L-arginine and NO homeostasis as well 
as the production of L-ornithine, a precursor to polyamines, necessary for cell proliferation. 
Arginase has also been shown to be a rate limiting step to this function in endothelial cells as 
well as being important in the production of proline, a building block for collagen [46, 47]. 
These studies imply not only the importance of arginase for endothelial cell proliferation but 
also its role in collagen synthesis, both vital for repairing the endothelial layer.
Increased arginase activity leads to decreased bioavailability of NO both through competing 
with eNOS for L-arginine, which is the substrate for NO production; and by uncoupling 
eNOS, leading to increased generation of reactive oxygen species (ROS) [48]. Arginase 
expression is stimulated by a number of proinflammatory factors like lipopolysaccharide, 
tumor necrosis factor-α and interferon-γ [47, 49] as well as oxidized LDL [50], glucose [51], 
reactive oxygen and nitrogen species [52] and hypoxia [53].
Arginase has been shown to be upregulated in atherosclerotic animal models [54, 55]. In 
a study of aged mice, blocking Arg2 led to increased NO production and decreased ROS 
production. It has also been shown that increased arginase activity is associated with 
endothelial dysfunction [56] and that overexpression of endothelial Arg2 induces endothelial 
dysfunction, hypertension and enhances atherosclerosis in mice [57]. Deleting Arg2 from 
endothelial cells in hypercholesterolemic mice reduced the formation of atherosclerotic 
lesions [58]. Endothelial arginase activity is elevated in conditions like hypertension and 
ischemia-reperfusion. This indicates a role in maintaining endothelial dysfunction in these 
states [59-61]. Furthermore, experiments with arginase inhibition have been shown to reduce 
aortic remodeling in chronically hypertensive rats probably inhibiting arginase-driven 
proliferation of smooth muscle cells and collagen synthesis [45]. This evidence implies an 
important role of arginase in the context of endothelial dysfunction and atherosclerosis.
Arginase expression is increased with elevated levels of glucose and its activity is increased 
in patients with T2D [62]. Arginase inhibition leads to improved endothelial function in 
patients with T2D and coronary artery disease (CAD) [63]. Pro-inflammatory cytokines 
increase arginase expression and activity in endothelial cells, whereas the anti-inflammatory 
cytokines IL-4, IL-10 and IL-13 increase arginase expression and activity in macrophages 
[64], mostly because of increased expression of Arg1 while Arg2 remains unchanged during 
stimulation [65]. This is in contrast to many animal models of atherosclerosis which indicate 
increased arginase activity with increased atherosclerotic burden [66]. 
Having established the role of arginase in both endothelial dysfunction and diabetes there is 
a need to investigate further its role in advanced human atherosclerosis. As a first step in this 
pursuit we decided to determine the expression of arginase in human atherosclerotic plaques 
and the functional interactions between the proinflammatory effect of ET-1 and arginase. 
Determination of endothelial function
Endothelial function can be measured by observing the vascular response to shear stress, as 
the dilatation/constriction is dependent on the bioavailability of NO. Various methods can be 
employed for this purpose [67]. An early method involves infusing acetylcholine directly into 
the coronary arteries and measuring the dilation/constriction. Although measuring endothe-
lial function directly in a clinically important vascular bed would be ideal, the invasiveness 
makes this a relatively impractical approach. 
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Peripheral measurements of endothelial function, such as flow mediated vasodilatation 
(FMD), have become more popular due to their non-invasive nature and established correlation 
to coronary endothelial function [68]. In addition studies indicate that FMD provides a 
meaningful addition to clinical risk factors in the evaluation of individual prognosis [69, 
70]. The method involves the use of ultrasonography to visualize and measure the lumen 
of the brachial artery. Using a blood pressure cuff around the forearm, the blood flow is 
stopped by increasing the pressure above that of the systolic blood pressure and after five 
minutes the flow is reinstated by deflating the cuff. This leads to a post-ischemic hyperemia. 
The resulting increase in shear stress leads to the release of calmodulin from the inhibitor 
caveolin. Calmodulin then activates eNOS which produces NO from L-arginin. NO diffuses 
to smooth muscle cells activating guanylate cyclase, thereby increasing intracellular cyclic 
guanosine monophosphate which causes relaxation in the smooth muscle cells, resulting in 
dilation of the artery. The measured dilatation reflects the bioavailability of NO. FMD is 
technically challenging and requires extensive training and standardization. 
Another method of measuring peripheral endothelial function is peripheral artery tonometry 
(PAT). PAT measures digital pulse amplitude in the fingertip through a device called Endo-
PAT (Itamar Medical, Caesarea, Israel) [71].  The device covers the tip of the index finger and 
uses a pneumatic plethysmograph that applies a uniform pressure to the surface of the finger, 
allowing measurement of pulse volume changes. The PAT signal is recorded at baseline and 
following 5 min arterial occlusion using an inflatable cuff while the other arm serves as 
a control. Although relying on the same phenomenon, post-ischemic reactive hyperemia, 
this method studies endothelial function in the small arterioles of the fingertip whereas 
FMD studies the conduit brachial artery. Impairment in peripheral endothelial function 
measured with Endo-PAT correlates with coronary microvascular function in patients 
with atherosclerosis [72]. These measurements can predict cardiovascular events beyond 
traditional risk factors in specific subsets of patients [73]. 
Venous occlusion plethysmography of the forearm is yet another method of investigating 
peripheral endothelial function. Using blood pressure cuffs to repeatedly stop and return 
blood flow the sensitive mercury-in-silastic strain-gauge measures changes in forearm 
circumference. The setup allows for the administration of vasoactive drugs and the response 
measured as a change in forearm circumference owing to increased blood flow. The other arm 
can be used as control because the doses used do not have a systemic effect. Acetylcholine 
and serotonin are usually used to stimulate endothelium-dependent vasodilatation. They 
cause an increase in intracellular calcium levels that in turn release calmodulin from caveolin 
and a resulting increase in NO in the same way as shear stress. This method is excellent to 
study the pharmacological effects of different drugs in the individual but unsuitable to screen 
many for excess risk. It is invasive in nature owing to the arterial cannula used for infusion 
but less so than coronary catheterization [74].
Endothelial progenitor cells as a marker of endothelial injury
The endothelial progenitor cell (EPC) is a stem cell originating from the bone marrow. 
Previously thought to develop from precursor to mature endothelial cell only during embryonic 
development, it was shown by Asahara and colleagues in 1997 that these cells taken from 
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adults can differentiate into mature endothelial phenotype ex vivo [75]. These cells are 
identified by different surface markers using flow cytometry of cell suspensions. The markers 
CD34 and CD133 indicate that the cell is a hematopoietic stem cell and the VEGF receptor, 
also known as KDR, indicates that the cell is going to evolve to an endothelial cell [76]. EPCs 
home to sites of ischemia and vascular injury as an endogenous repair mechanism of damaged 
endothelium. They are thought to contribute to re-endothelialization, neovascularization and 
the restoration of blood flow at the site of injury [77]. Consequently, reduced numbers and 
diminished function of EPCs have been linked to endothelial dysfunction [78] as well as 
increased risk for atherosclerosis and cardiovascular morbidity and mortality (Figure 6) [79]. 
Cardiovascular risk factors have been linked to the number and function of circulating 
EPC. A reduced number of EPC is observed in patients with the metabolic syndrome [80], 
hypertension [81], family history of CAD [82], and hyperlipidemia [83]. Accumulating 
evidence indicates that diabetes mellitus is associated with impaired number and function 
of EPC. The number of EPC is reduced in patients with T2D and was found to negatively 
correlate with disease severity score [84], also increasing the risk of cardiovascular mortality 
and morbidity [85]. 
Figure 6. EPC mirror the natural history of atherosclerosis. The level of EPC (set at 
maximal in patients with normal arterial anatomy and function) starts to decline when 
cardiovascular risk factors appear in high risk patients. Further, EPC progressively decline 
with initial vascular remodeling (IMT), plaque development and progression. Lower EPCs 
are markers of high risk for future cardiovascular events. Finally, when complications occur 
(such as AMI or stroke) EPCs should be increased by bone marrow mobilization. When this 
mechanism is perturbed, a worse outcome can be predicted. EPC= endothelial progenitor 
cell. Circulation Research.2012; 110: 624-637.
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Studies have indicated that there is a dynamic interplay between EPCs, reactive oxygen 
species and inflammation thus implicating EPCs in vascular repair [86]. In addition there 
seems to be an increase in the number of EPCs when individuals are treated with medication 
with anti-inflammatory properties like statins and angiotensin converting enzyme inhibitors 
in patients with cardiovascular disease [87]. The impact of ET receptor blockers on EPC 
numbers in patients with diabetes and cardiovascular disease remains unknown, however. 
Summary
Based on the evidence presented above, there is a need to investigate further the effects of 
longer term ET receptor blockade on both macro- and microvascular function in patients 
with T2D and vascular complications. This is an ever increasing patient population with 
considerable mortality and morbidity and as of yet the therapeutic options remain insufficient. 
There is also a question whether to selectively block the ETA receptor or to block both ETA 
and ETB for best therapeutic effect. ETB causes vasodilatation when activated on endothelial 
cells under normal circumstances but as presented, with the development of atherosclerosis 
there seems to be a redistribution of the ETB receptor to cells involved in the atherosclerotic 
plaque. Furthermore, it seems to be a contributing factor to endothelial dysfunction instead of 
vasodilatation. Both arginase and ET-1 play a role in endothelial dysfunction as well as in the 
development of vascular complications in T2D. The relationship between the two has never 
before been investigated in atherosclerotic disease. 
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PURPOSE
The overall aim of the project was to investigate the role of ET-1 for vascular dysfunction in 
atherosclerosis and type 2 diabetes and to evaluate the efficacy of ET receptor blockade to 
improve endothelial function. The specific aims were to: 
I.  Investigate the effect of oral administration of a combined ETA/ETB receptor blocker on 
endothelial function in patients with type 2 diabetes and microvascular dysfunction (I)
II.  Compare the effects of selective ETA receptor blockade and combined ETA/ETB receptor 
blockade on endothelial function in patients with type 2 diabetes and coronary artery 
disease (II)
III.  Investigate the effect of oral administration of a combined ETA/ETB receptor blocker 
on the recruitment of endothelial progenitor cells in patients with type 2 diabetes and 
microvascular dysfunction (III)
IV.  Determine the gene and protein expression of ET-1 and its receptors in the atherosclerotic 
plaque and its relation to arginase (IV)
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Table 1. Baseline characteristics of study subjects in studies I and III. Values are presented 
as mean±SD or number of patients (n). ACE= angiotensin converting enzyme. ARB= 
angiotensin receptor blocker.
Placebo (n=24) Bosentan (n=22)
Age, years 63±9 62±8
Male/female, n 19/5 18/4 
Body mass index, kg/m2 31.5±4.0 28.9±7.4
Waist circumference, cm 111±11 109±10
Current smokers, n 1 2
Diabetes duration, years 17.7±9.6 14.9±6.3
Coronary artery disease, n
Peripheral artery disease, n
Retinopathy
Non-proliferative, n
Proliferative, n
Neuropathy
Moderate, n
Severe, n
9
4
10
5
5
6
10
0
8
2
7
2
Treatment
Insulin, n 16 18
Oral glucose-lowering agents, n 16 13
Aspirin, n 15 13
Betablocker, n 8 12
ACE inhibitor/ARB, n 19 20
Calcium channel blocker, n 9 9
Statins, n 13 14
MATERIALS AND METHODS
Study subjects
The studies were performed in accordance with the Declaration of Helsinki and were ap-
proved by the local ethics committee at Karolinska University Hospital. All patients gave 
their oral and written informed consent. 
Studies I and III 
A total of 46 patients with T2D of at least two years duration and microalbuminuria were 
recruited from the department of Endocrinology, Metabolism and Diabetes at Karolinska 
University Hospital. The patients were classified as having diabetes mellitus if fasting blood 
glucose exceeded 7.0 mmol/L (on at least on two occasions) or blood glucose concentration 
was >11.0 mmol/L two h after an oral glucose loading (75 g). Albuminuria was defined 
as urine albumin concentration >20 mg/L or >30 mg/L per 12 h and a ratio of albumin/
creatinine >3.0 mg/mmol. Exclusion criteria were recent myocardial infarction or unstable 
angina (within the last three months), decompensated heart failure, changed dose of any 
vasodilator drug during the preceding six weeks, childbearing potential, impaired hepatic 
function (2 times the normal limit of serum aminotransferases), ongoing treatment with 
glibenclamide, cyclosporine or warfarin or any concomitant disease that may have interfered 
with the possibility for the patients to comply with or complete the study protocol. The 
baseline characteristics of the patients included in studies I and III are presented in Table 1.
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Table 2. Baseline characteristics of study subjects in study II. Values are presented as 
mean±SD. BMI=body mass index, HbA1c=glycosylated hemoglobin, eGFR=estimated 
glomerular filtration rate. ACEi=angiotensin converting enzyme inhibitor, ARB= 
angiotensin receptor blocker.
Characteristics n=12
Age, years 64.8±9.0
Height, cm 175±5
Weight, kg 87.8±10.9
BMI, kg/m2 28.4±2.3
Hip-waist ratio 1.0±0.04
Glucose, mmol/L 8.4±1.9
HbA1c, mmol/mol 57.8±8.0
Creatinine, μmol/L 84±16
eGFR, mL/min 99±21
Hemoglobin, g/L 144±13
C-reactive protein, mg/L 2.1±2.0
Triglycerides, mmol/L 1.7±1.0
Cholesterol, mmol/L 4.2±1.0
HDL cholesterol, mmol/L 1.2±0.4
LDL cholesterol, mmol/L 2.2±0.9
Systolic BP, mmHg 138±13
Diastolic BP, mmHg 75±12
Treatment
Aspirin, n 10
Oral antidiabetic agent, n 10
Insulin, n 6
Beta blocker, n 7
Nitrates, long acting, n 2
ACEi/ARB, n 9
Calcium channel blocker, n 9
Statin, n 10
Other antihypertensive treatment, n 2
Study II
In study II we included 12 patients with T2D of at least two years duration and known CAD. 
They were recruited from the department of Cardiology, Karolinska University Hospital, 
during follow-up after coronary revascularization. Patients were classified as having diabetes 
mellitus if fasting blood glucose exceeded 7.0 mmol/L (on at least two occasions) or blood 
glucose concentration was >11.0 mmol/L after an oral glucose loading (75 g). CAD was 
defined as either previous coronary artery bypass surgery (CABG) or percutaneous coronary 
intervention (PCI). Exclusion criteria were myocardial infarction or unstable angina within 
the last six weeks, known Raynaud’s phenomenon, peripheral vascular disease, arterial 
shunting or other vascular surgery of the study arm, change in dose of any vasodilator drug 
during the preceding six weeks, ongoing treatment with warfarin or any concomitant disease 
that may have interfered with the possibility for the patients to comply with or complete the 
study protocol. The baseline characteristics are presented in Table 2. 
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Table 2. Baseline characteristics of study subjects in study II. Values are presented as 
mean±SD. BMI=body mass index, HbA1c=glycosylated hemoglobin, eGFR=estimated 
glomerular filtration rate. ACEi=angiotensin converting enzyme inhibitor, ARB= 
angiotensin receptor blocker.
Characteristics n=12
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BMI, kg/m2 28.4±2.3
Hip-waist ratio 1.0±0.04
Glucose, mmol/L 8.4±1.9
HbA1c, mmol/mol 57.8±8.0
Creatinine, μmol/L 84±16
eGFR, mL/min 99±21
Hemoglobin, g/L 144±13
C-reactive protein, mg/L 2.1±2.0
Triglycerides, mmol/L 1.7±1.0
Cholesterol, mmol/L 4.2±1.0
HDL cholesterol, mmol/L 1.2±0.4
LDL cholesterol, mmol/L 2.2±0.9
Systolic BP, mmHg 138±13
Diastolic BP, mmHg 75±12
Treatment
Aspirin, n 10
Oral antidiabetic agent, n 10
Insulin, n 6
Beta blocker, n 7
Nitrates, long acting, n 2
ACEi/ARB, n 9
Calcium channel blocker, n 9
Statin, n 10
Other antihypertensive treatment, n 2
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shunting or other vascular surgery of the study arm, change in dose of any vasodilator drug 
during the preceding six weeks, ongoing treatment with warfarin or any concomitant disease 
that may have interfered with the possibility for the patients to comply with or complete the 
study protocol. The baseline characteristics are presented in Table 2. 
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Study IV
In study IV we had access to the Biobank of Karolinska Endarterectomies (BIKE) which is 
a database comprised of atherosclerotic plaques removed during carotid endarterectomies 
of either symptomatic or asymptomatic patients. Control tissue was obtained from iliac 
arteries of organ donors without atherosclerotic disease. Several clinical variables were 
registered, including gender, clinical chemistry, medication, and last recorded symptoms of 
plaque instability prior to the endarterectomy procedure. At the time of the study the database 
included 127 patients and 10 normal arteries. Patients undergoing surgery for symptomatic or 
asymptomatic high-grade carotid stenosis at the Department of Vascular Surgery, Karolinska 
University Hospital, were consecutively enrolled in the study and clinical data recorded on 
admission. Symptoms of plaque instability were defined as transient ischemic attack (TIA), 
minor stroke (MS) and amaurosis fugax (retinal TIA). Patients without qualifying symptoms 
within six months prior to surgery were categorized as asymptomatic. All samples were 
collected with informed consent from patients, organ donors or their guardians.
Methods
Flow Mediated Vasodilatation and Pulse Amplitude Tonometry
Study I uses two methods for determination of endothelial function: Flow mediated 
vasodilatation (FMD) and pulse amplitude tonometry (PAT). The patient is situated in 
a relaxed semi-recumbent position, a blood pressure cuff is placed on the forearm. An 
ultrasound probe is carefully positioned proximal to the cuff to visualize the brachial 
artery. On the index finger the Endo PAT probe is placed on index finger of both hands. The 
experiment begins with the blood pressure cuff being inflated to cause local ischemia of the 
forearm. After 5 minutes of ischemia, the pressure is released from the cuff reinstating blood 
flow. During the reperfusion the flow mediated vasodilatation is recorded on the ultrasound 
machine and the changes in the pulse amplitude in the index finger measured by the Endo-
PAT device. Both methods make use of the physiological phenomenon called post-occlusive 
hyperemia resulting from the ischemia-reperfusion caused by the blood pressure cuff. The 
hyperemia leads to increased shear stress which stimulates NO release from the endothelium, 
resulting in an increase in the diameter of the brachial artery [41] (FMD) or the small artery 
pulse amplitude (PAT) in the fingertip (Figure 7) [88, 89]. Pulse amplitude was recorded 
electronically in both fingers and analyzed by a computerized, automated algorithm (Itamar 
Medical). The change from the baseline measurement is expressed as the reactive hyperemia 
index (RHI) which in part reflects vasodilator function of the digital microcirculation [90]. 
Previous evaluation of this method has demonstrated that RHI is to a large part dependent on 
NO bioavailability [88]. Endothelium-independent vasodilatation (EIDV) was determined 
following sublingual administration of nitroglycerine (0.4 mg). 
This measurement has been shown to be an independent predictor of adverse cardiac events 
in the Framingham cohort [91]. FMD is calculated as per cent change from baseline in the 
diameter of the brachial artery measured with an ultrasound probe and the change in the 
diameter that is caused by the post-occlusive hyperemia. FMD has been shown to be impaired 
as a consequence of a range of classical risk factors [92]. 
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Venous Occlusion Plethysmography
Study II uses venous occlusion plethysmography [93]. This is an invasive method capable of 
directly measuring the endothelium-dependent and endothelium-independent vasodilatation. 
Although invasive, this kind of study is valuable as it can measure immediate effects of infused 
agents on the endothelial function [94]. Forearm blood flow is measured simultaneously in 
both arms using the mercury-in-silastic strain-gauge technique. A venous occlusion cuff placed 
around the upper arm is inflated to 40 mmHg for 10 sec to obtain recordings of arterial inflow 
followed by deflation for 5 sec. During recordings of blood flow the circulation of the hands 
is occluded by a cuff inflated to 30 mmHg above the systolic blood pressure. A percutaneous 
catheter is inserted under local anesthesia in the brachial artery of the non-dominant arm for 
infusions and collection of blood samples. Another catheter is inserted in a deep cubital vein 
on the same arm for blood sampling. Endothelium-dependent vasodilatation is determined by 
intra-arterial infusion of serotonin (Ser; 21, 70 and 210 ng/min). Endothelium-independent 
vasodilatation is determined by infusion of sodium nitroprusside (SNP; 0.3, 1 and 3 µg/
min). Each dose is given for 2 min at a rate of 2.5 ml/min. The NO-dependent property of 
the vasodilatation induced by serotonin has previously been validated in this model by our 
group [63].
Figure 7. Pulse amplitude tonometry and flow-mediated vasodilatation examined 
simultaneously. The PAT signal represents endothelium-dependent dilatation in microvessels 
in the finger tip. FMD measures endothelium-dependent dilatation in a larger conduit artery 
(a. brachialis).
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Transcutaneous Oxygen Tension (TcPO2)
TcPO2 is a noninvasive method to measure to quantify skin oxygenation. It is used in research 
as well as clinically to evaluate ulcer healing in diabetic ulcers and peripheral artery disease 
[95]. In study II it was used simultaneously with the venous occlusion plethysmography, 
a transcutaneous (tc) pO2 probe (PF 5040, Perimed, Järfälla, Sweden) was attached to the 
forearm at the start of the study protocol for continuous recording. Readout was performed 
before and at the end of the infusions of antagonists in a standardized fashion and a photograph 
was taken to ensure the same placement on the different study occasions. The measured unit 
is mmHg.
 
Laser Doppler Flowmetry
Laser Doppler flowmetry is a technique based on the scattering of laser light by red blood 
cells. This corresponds to the blood flow in the skin underlying the probe and is a measure-
ment of the skin microcirculation. When the beam of light encounters red blood cells, it scat-
ters and the shift in light wavelength frequency depends on the blood cells average velocity 
(Figure 8) [96]. The sampling volume of current laser Doppler devices is between 0.5 and 1 
mm3, so the flow measured represents the average in at least 50 vessels, including arterioles, 
capillaries and venules of variable size and direction. The technique measures relative change 
in perfusion (called perfusion units, PU) which makes it possible to detect change in a given 
area after some type of challenge or treatment. The laser Doppler probe was placed on the 
forearm during setup of the experiment in study II and readout performed after conclusion of 
the venous occlusion plethysmography. 
Flow Cytometry 
Flow cytometry is a method employing laser light scattering properties to count cell types. 
When coupled to fluorescence labeling using different markers it is possible to label cells 
to count the different subtypes in a given sample. In study III, this method was used to 
isolate and count endothelial progenitor cells in a venous blood sample (10ml EDTA tubes). 
Different subpopulations can then be identified by using the hematopoietic progenitor cell 
marker CD34, the immature hematopoietic progenitor cell marker CD133, and the endothelial 
cell receptor VEGFR2 (vascular endothelial growth factor receptor-2, also known as kinase 
domain receptor, KDR), as described previously [97, 98]. Peripheral blood mononuclear cells 
(PBMC) are incubated with fluoresceinisothiocyanate (FITC)-conjugated anti-human CD34 
monoclonal antibody (mAb) (BD Biosciences), phycoerythrin (PE)-conjugated anti-human 
Figure 8. Laser Doppler showing close up of the probe during resting conditions (1) and 
during heating (2). Courtesy of Perimed. 
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CD133 mAb (Milteny Biotec) and allophycocyanin-conjugated monoclonal anti-VEGFR2 
(R&D Systems) for 60 min at +4°C. The cytometer (CyAn, Dako, Denmark) then counts the 
frequency of peripheral blood cells positive for these reagents determined by a two-dimensional 
side-scatter fluorescence dot-plot analysis of the samples, after appropriate gating.
Study Protocols
Study I 
The study was a placebo controlled, double blinded randomized trial including patients with 
T2D of at least 2 years of duration and documented albuminuria as a surrogate marker of 
vascular dysfunction. The study included a total of 46 patients of which 22 were randomized 
to receive the dual ETA/ETB receptor antagonist bosentan 250 mg bid and 24 patients were 
randomized to the placebo group (Figure 9). Treatment duration was 4 weeks and the patients 
underwent measurement of endothelial function at baseline and after the treatment duration. 
The primary endpoint for study I was change in microvascular function as measured by 
endo-PAT. Secondary endpoint was the change in endothelial function of the brachial artery 
measured by FMD.
Figure 9. Flowchart for inclusion of patients in Studies I and II. 
Assessed for eligibility
(n= 161)
Excluded  (n=105)
Not meeting inclusion criteria
(n= 41)
Refused to participate
(n= 64)
Analyzed  (n= 25)
Excluded from analysis  (n=3)
One due to technical problems 
with analysis
Two due to changes in 
vasoactive drug therapy
Discontinued intervention
(n=3)
One due to flushing and 
edema
Two due to respiratory tract 
infection
Bosentan 
(n=28)
Discontinued intervention
(n= 2)
One due do ischemic stroke 
One due to a concomitant 
condition interfering with the 
protocol
Placebo
(n=28)
Analyzed  (n= 26)
Excluded from analysis  (n=2)
Two due to failure to take 
medication 
Allocation
Analysis
Follow-Up
Enrollment
Randomized 
(n=56)
Included in final analysis 
(n=22)
Included in final analysis 
(n=24)
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Study II
Twelve patients with T2D and CAD were included in this trial with cross-over design and 
blinded evaluation comparing the effects of selective ETA receptor blockade and dual ETA/
ETB receptor blockade. Endothelium-dependent and endothelium-independent vasodilatation 
was measured using venous occlusion plethysmography measuring forearm blood flow 
during intra-arterial infusions of serotonin and nitroprusside, respectively. The determination 
of endothelial function was performed before and after 60 minutes of intra-arterial infusion 
of either the selective ETA antagonist BQ123 or the combination of BQ123 and the ETB 
antagonist BQ788 (Figure 10). 
A laser Doppler probe as well as a TcPO2 probe were attached to the skin on the arm at the 
beginning of the experiment. The measured values are respectively, a mean value of flow 
during a period of time around 2 minutes, given in perfusion units (PU), and oxygen pressure 
in mmHg. At the end of the study the laser Doppler probe measured the thermal reactivity 
after 15 minutes of heating (44°C). 
 
Study III
This study is based on the patient material from Study I. Blood samples were taken at base-
line and at follow-up. Of the initial 46 patients in the study, blood samples for analysis of 
EPC subpopulations were successfully collected from 36 patients. 
Different subpopulations were identified by using the hematopoietic progenitor cell markers 
CD34, the immature hematopoietic progenitor cell marker CD133, and the endothelial cell 
receptor VEGFR2. In addition to EPC subpopulations the number of apoptotic progenitor 
cells were measured using the Annexin-V Apoptosis detection kit. Circulating ET-1 was 
measured as a marker of activated endothelium and von Willebrand factor and ICAM-
1 were used as markers of endothelial damage and were determined using enzyme linked 
immunoassay (ELISA).
Study IV
Two non-overlapping BiKE microarray datasets were used to determine the mRNA levels of 
genes of interest in human plaques. The larger ‘discovery’ dataset comprised n=127 carotid 
plaques and n=10 normal arteries. The smaller ‘validation’ dataset comprised n=50 plaques 
and n=5 normal arteries. Plaque material was analyzed with regard to mRNA expression of 
the genes  EDN1, EDNRA, EDNRB, ARG1 and ARG2. To investigate the protein expression 
Figure 10. Protocol for study II. 
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of the genes of interest, the plaques were stained using immunohistochemistry, both single 
and double staining protocols to ascertain co-localization. Next the cells that showed co-
localization of ET-1 and arginase, endothelial cells and macrophages were used in functional 
testing for a possible connection. The cells were stimulated with ET-1 and the mRNA 
expression of ARG1 and ARG2 was determined by qPCR. To further explore the ET-1 
stimulation, arginase activity  was measured using spectrophotometry in both endothelial 
cells and macrophages. In the macrophages, reactive oxygen species were measured using 
electron spin resonance (ESR). 
Biochemical analyses
Blood tests in studies I, II and III
In studies I and III fasting plasma glucose, Hb1Ac (Mono S), blood lipids, liver function 
tests were accessed with standard methods according to local laboratory routines. Insulin-
like growth factor-1 (IGF-1) was analyzed by radioimmunoassay (RIA) and calculated using 
an age adjusted SD score: (10log(IGF-I level)-0.00625*age-2.555)/0.104 [99]. Insulin-
like growth factor  binding protein-1 (IGFBP-1) was determined by RIA [100]. ET-1 was 
measured using ELISA (R&D systems, Minneapolis, USA). High-sensitive C-reactive 
protein was analyzed using turbidimetry (Beckman Coulter, Fullerton CA, USA).
For study II, screening blood samples were taken on the morning of the first visit for analysis 
of blood glucose, HbA1C, total cholesterol, low-density lipoprotein cholesterol, high-density 
lipoprotein cholesterol, triglycerides, C-reactive protein, creatinine, IGF-1 and IGFBP-1. 
Plasma ET-1 levels were measured by chemiluminescent ELISA (Quantiglo kit, R&D, 
Abingdon, UK) before and after completion of the treatment protocol. Glomerular filtration 
rate (eGFR) was estimated using the Cockroft-Gault formula. 
Quantitative real time PCR for mRNA quantification
To estimate the translation activity of a specific gene it is possible to measure the amount of 
messenger RNA that is present. The method used in this work to quantify amounts of mRNA 
from a single gene is called polymerase chain reaction (PCR) and relies on the generation 
of cDNA, hybridization of complementary DNA primers and probes for activating DNA 
polymerase, and repeated heating/cooling cycles for the amplification of the probed gene. 
Real time PCR amplifies the target genes mRNA to measurable levels real time and makes 
use of gene specific probes produced commercially [101]. This method is utilized in study IV 
to measure mRNA levels of atherosclerotic plaques as well as in cell cultures. For qPCR, total 
RNA was reverse-transcribed using High Capacity RNA-to-cDNA kit (4387406, Applied 
Biosystems, Life Technologies, Carlsbad, CA). PCR amplification was done in 96-well 
plates in 7900 HT real-time PCR system (Applied Biosystems), using TaqMan® Universal 
PCR Master Mix (Applied Biosystems) and TaqMan® Gene Expression Assays (Arginase 
1=ARG1: HS00968979_M1, Arginase 2=ARG2: HS00982833_M1, Applied Biosystems). 
All samples were measured in duplicates. Results were normalized to the equal mass of total 
RNA as well as the Ct values of RPLPO housekeeping control (HS99999902_M1). The 
relative amount of target gene mRNA was calculated by 2-ΔΔCt method and presented as 
fold change compared to the baseline expression.
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Immunohistochemistry
Immunohistochemistry is a process to identify specific proteins in cells and tissue. The 
technique relies on the specific binding of antibodies to their antigens. In this way the protein 
of interest is localised in the tissue by the antibody which is coupled to an enzyme that can 
catalyse a colour reaction that can be visualised in a common light microscope or if the 
chromogen is fluorescent, a fluorescence microscope. This is a qualitative method that allows 
specific receptors and proteins to be located in tissues as well as co-localisation with other 
proteins by using double stainings. One of the weaknesses of the method is the specificity 
of the antibody used. If specificity is lacking the antibody can bind to other non-relevant 
structures. This error can be avoided by testing the antibody with antigen pre-adsorption 
[102]. In study VI the following antibodies were used for immunohistochemical staining: 
a polyclonal rabbit anti-human ET-1 (1:250; Abcam, Cambridge, UK), polyclonal rabbit 
anti-human ETB (1:100; Alomone labs, Jerusalem, Israel), polyclonal rabbit anti-human ETA 
(1:500; Alomone labs), Monoclonal mouse anti-human Arg1 and Arg2 (1:50, Atlas antibodies, 
Bromma, Sweden), monoclonal mouse anti-human CD163 (1:200; Dako, Glostrup, 
Denmark), monoclonal mouse anti-human von Willebrand Factor (VWF; 1:4000; Dako), 
and monoclonal mouse anti-human smooth muscle α-actin (1:600; Dako). Isotype rabbit 
and mouse IgG were used as negative controls. In brief, 5 µm sections were deparaffinized 
in Clear (Histolab, Gothenburg, Sweden) and rehydrated in ethanol. For antigen retrieval, 
slides were subjected to high-pressure boiling in DIVA buffer (pH 6.0). After blocking with 
Background Sniper, primary antibodies diluted in Da Vinci Green solution were applied and 
incubated at room temperature for 1 h. Detection was performed with Mach3 Probe and 
Mach3 Polymer Detection technology (BioCare Medical, Pacheco, CA, USA), using Warp 
Red and Vina Green, stained in a consecutive manner using MACH 2 double stain kit 2. 
Rabbit IgG1 and mouse IgG1 (BioCare Medical) were utilized as negative controls. The 
slides were then counterstained with Hematoxylin QS (Vector Laboratories, Burlingame, 
CA, USA), dehydrated and mounted in Pertex (Histolab). Images were taken using a Nikon 
OPTIPHOT-2 microscope equipped with digital camera and NIS-Elements software.
Arginase activity determined by spectrophotometry
Spectrophotometry is a method that measures the intensity of light passed through a sample 
solution of the chemical in question. Each compound or chemical absorbs, reflects or transmits 
light over a certain range of wavelength. This method is widely used for quantitative analysis 
and is particularly popular in enzyme-catalyzed reactions which we used in study IV to analyse 
arginase activity from different cell cultures. Endothelial cells and THP-1 macrophages were 
lysed by using fresh 1 mM EDTA, Triton X-100 (0.1%, MERCK, Darmstadt, Germany) and 
protease inhibitors (Roche) in PBS. Each sample was incubated at 37 °C for 1 h with either 
l-arginine (50 mM Tris⋅HCl at pH 9.7) + vehicle, l-arginine + ABH (0.1 mM; Enzo Clinical 
Labs, Farmingdale, NY, USA) or with l-arginine + nor-NOHA (1 mM). The concentration of 
the end product urea was determined by using spectrophotometry. The inhibition induced by 
arginase inhibitor was calculated as the difference between the urea production from vehicle-
treated and inhibitor-treated samples.
Electron spin resonance for production of reactive oxygen species (ROS)
As reactive oxygen species have a half-life ranging from nanoseconds to a few seconds, the 
methods used to accurately quantify these short-lived chemical compounds have to have 
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fast reaction times and produce longer lived signal compounds [103]. One of those methods 
employs a hydroxylamine spin probe that binds to ROS and creates a stable compound and 
produces a measurable signal. Reactive oxygen species are molecules that have free radicals. 
Radicals have an unpaired electron and this causes them to have magnetic moment that 
can be detected by electron spin spectroscopy using a magnetic field [104]. Macrophages 
were treated with the arginase inhibitor (S)-amino-6-boronohexanoic acid (ABH; 1 mM), 
or vehicle for 30 min prior to incubation with ET-1 (1 nM). After 24 h incubation, the cells 
were incubated with 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH, 
200 µM) for 30 min. The cell suspensions were frozen in liquid nitrogen. Reactive oxygen 
species (ROS) formation was detected by ESR using the following setting: center field 1.99 
g, microwave power 1 mW, modulation amplitude 9 G, sweep time 10 s, number of scans 10, 
field sweep 60 G. The amount of CM• was determined from the calibration using 3-carboxy-
proxyl (CP•, Noxygen Science Transfer & Diagnostics GmbH).
Statistical analyses
In study I data are presented as mean and standard deviation. A two-sided P-value <0.05 was 
considered significant. The data for analyses between the groups was calculated as change 
from baseline after completed therapy. Group comparisons were made using t-test. Data 
that were not normally distributed were log transformed. The number of patients per group 
needed to detect a difference in RHI=0.3 with a power of 80% with a two-tailed t-test at the 
5% level was calculated to be 22 with SD=0.35 for difference in RHI. The improvement 
in by 0.3 was based on a previous study [89]. All statistical analyses were performed with 
GraphPad Prism 6.
 
In study II differences in the change in forearm blood flow induced by serotonin and SNP 
between the two different treatments were assessed by 2-way analysis of variance. Changes 
in baseline flow were assessed by 1-way repeated-measures analysis of variance followed by 
the Bonferroni multiple comparison test. Based on a previous study performed using a similar 
study protocol we have observed improvement in endothelium-dependent vasodilatation by 
30% following dual receptor blockade [43]. Assuming similar effect in the present study the 
number of subjects was calculated to be 12 (α = 0.05 and 80% power). A value of P<0.05 
was considered significant. All statistical analyses were performed with GraphPad Prism 6.
In study III continuous variables were tested for normal distribution with the Kolmogorov-
Smirnov test. Non-normally distributed continuous variables groups were compared by the 
Mann-Whitney U test, while others were analyzed by t test (2 sided, including Levene’s test 
for equality of variances). Bivariate correlation (Spearman’s rank correlation coefficient) was 
used to correlate circulating EPC counts with risk factors or drug treatment. Comparisons 
between before and after treatment were compared using a paired test. Statistical significance 
was assumed if a null hypothesis could be rejected at p<0.05. All statistical analyses were 
performed with IBM-SPSS, version 19.0 (IBM Inc.).
In study IV microarray dataset analyses were performed using a linear regression model 
adjusted for age and gender and a two-sided Student’s t-test assuming non-equal deviation, 
with Bonferroni correction for multiple comparisons. Details of these analyses were previously 
described [105]. Spearman correlations were calculated to determine the association between 
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mRNA expression levels from microarrays (weak if Spearman r<0.3, moderate 0.3<r<0.6 
and strong r>0.6). Results from in vitro experiments were evaluated by the non-parametric 
Kruskal-Wallis test or ANOVA when appropriate. Data are presented as mean fold change 
with SEM. All calculations were performed using GraphPad Prism 6 and Bioconductor 
software. In all analyses p-value <0.05 was considered significant.
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Results 
Study I
Study subjects
Three patients in the active treatment arm (bosentan) stopped the study because of adverse 
events (one due to facial flushing and oedema, two due to respiratory tract infection) and 
three patients were excluded due to protocol violation (one patient due to only 4 min arterial 
occlusion, two patients due to change in vasodilatory medication during the study period). 
In the placebo group, four patients were excluded. One of these suffered an ischaemic 
stroke, two patients did not take the study medication as instructed and one patient was 
excluded due to a concomitant condition that interfered with his/her ability to comply with 
the study  protocol. A total of 46 patients remained in the final analysis. The two groups were 
well matched at baseline with no significant differences in their baseline characteristics or 
medication (Table 1). 
Bosentan increased microvascular endothelial function 
The primary endpoint was change in digital RHI from baseline to follow-up measured by 
Endo-PAT. Baseline RHI was 1.82±0.50 for the entire study population. Baseline RHI was 
similar in the two groups. RHI did not change significantly from baseline (1.84±0.49) to 
follow-up (1.87±0.47) in the placebo group. In the bosentan-treated group, RHI increased 
from 1.73±0.43 at baseline to 2.08±0.59 at follow-up (P<0.05; Figure 11A). The change in 
RHI during the 4 weeks of treatment with bosentan was significantly greater than that of the 
placebo group (0.38, 95% CI 0.02, 0.74; Figure 11B). The change in RHI did not correlate 
to change in systolic blood pressure (r=0.16; p=0.28). Nitroglycerine-induced PAT signal did 
not change with treatment (1.20±0.44 at baseline and 1.24±0.30 at follow-up). 
Baseline brachial artery FMD was comparable in the two groups. After 4 weeks treatment 
there was no significant change in FMD (0.016, 95% CI -1.38, 1.0; Table 3) or nitroglycerine-
induced brachial artery dilatation in either group.
 
Figure 11. A: Reactive hyperaemia index (RHI) at baseline and follow-up for the placebo 
and bosentan groups. B: Change in RHI from baseline inthe two groups. Values are 
mean±SD; *p<0.05.
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Increase in plasma ET-1 but no change in urine albumin/creatinine ratio
Treatment with bosentan resulted in a significant drop in hemoglobin from 134 g/L to 127 g/L 
(P<0.001; Table 3). There was no significant change in urine albumin/creatinine ratio in either 
group. During treatment there were no changes in lipid profile or blood glucose levels. Plasma 
levels of ET-1 increased from 1.5±0.6 pg/mL at baseline to 2.6±1.2 pg/mL (P<0.001) in the 
bosentan group which could be expected due to reduced ETB receptor-mediated clearance 
of ET-1. ET-1 levels did not change in the placebo group (1.8±0.9 pg/mL at baseline and 
1.7±0.7 pg/mL at follow-up). IGF-1 and IGFBP-1 did not differ at baseline between groups 
and were not affected by treatment. There was no change in hepatic transaminases during the 
treatment period.
Table 3. Treatment effects of 4 weeks treatment with bosentan. Values are presented as 
mean±SD. a P<0.001 vs. baseline. FMD; flow-mediated dilatation, SBP; systolic blood 
pressure, DBP; diastolic blood pressure, IGF-1 SD-score; age adjusted insulin-like 
growth factor-1, IGFBP-1; insulin-like growth factor binding protein-1, ASAT; aspartat 
aminotransferase, ALAT; alanine aminotransferase, VTI; velocity time integral.
Placebo Bosentan
Baseline Follow up Baseline Follow up
FMD, change (%)
Brachial artery basal 
diameter (mm)
Brachial artery VTI (cm)
3.3±2.7
3.9±0.7
21±6.9
3.2±2.0
3.9±0.7
23±6.9
3.1±2.8
3.9±0.6
29±11
3.2±2.7
4.0±0.7
28±6.7
Systolic BP (mmHg) 151±25 150±21 149±24 143±18
Diastolic BP (mmHg) 78±9 79±8 81±10 77±11
Hemoglobin (g/l) 136.5±13.6 137.2±15.1 134.0±16.1 127.3±15.1a
Glucose (mmol/l) 9.5±3.9 9.9±3.6 8.6±2.5 8.4±2.7
Insulin (pmol/l) 107.5±143.1 95.8±97.6 129.2±121.3 118.3±93.1
IGF-1 (SD-score) -0.47±1.4 -0.37±1.6 -0.39±1.2 -0.87±1.1
IGFBP-1 (µg/l) 50.9±33.8 51.3±33.8 50.7±35.6 54.1±30.7
ASAT (µcat/l) 0.51±0.45 0.48±0.25 0.39±0.14 0.48±0.31
ALAT (µcat/l) 0.61±0.71 0.56±0.53 0.47±0.24 0.58±0.42
uAlb/Crea (mg/mmol) 46.3±58.0 39.0±70.7 46.9±77.1 31.6±47.0
Triglycerides (mmol/l) 1.6±0.8 1.7±0.7 1.5±0.7 1.6±0.7
Total cholesterol (mmol/l) 4.0±0.9 4.1±1.0 3.7±0.7 3.7±0.5
HDL cholesterol (mmol/l) 1.0±0.3 1.0±0.3 0.9±0.1 0.8±0.2
LDL cholesterol (mmol/l) 2.4±0.9 2.4±0.9 2.1±0.5 2.1±0.5
HbA1c, DCCT (%)
HbA1c, IFCC (mmol/mol) 
8.0±1.4
64.0±15.0
8.0±1.4
64.3±15.4
7.4±1.1
57.8±12.1
7.4±1.0
56.9±11.1
Creatinine (µmol/l) 101.9±51.3 107.3±56.6 125.2±96.0 115.7±85.0
hsCRP (mg/l) 3.0±3.3 3.4±2.9 3.2±3.2 4.8±7.7
Endothelin-1 (pg/ml) 1.8±0.9 1.7±0.8 1.5±0.6 2.6±1.1a
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Study II
Study subjects 
The patient characteristics are presented in Table 2. Blood pressure or heart rate did not 
change during the infusions of the ET receptor blockers. No adverse effects occurred during 
any of the experiments.
Both treatments improved endothelial function but only dual blockade increased basal flow
Both selective ETA receptor blockade and dual ETA/ETB receptor blockade induced 
significant improvement in endothelium-dependent vasodilatation in patients with T2D 
and CAD  (Figure 12). The magnitude of improvement did not differ between the two 
treatment regimes. Dual ETA/ETB blockade significantly increased basal blood flow (36.4±3 
to 47.6±4 mL/min/1000mL, p=0.006) whereas ETA blockade did not (37.4±3 to 42.1±3 mL/
min/1000mL). Endothelium-independent vasodilatation was also increased significantly by 
both interventions (p<0.001).
Laser Doppler flow increased with ETA blockade whereas TcPO2 increased with dual blockade
Laser Doppler flow was significantly higher after infusion of BQ123 than at baseline whereas 
there was a non-significant trend towards increased flow after infusion of BQ123+BQ788 
(Figure 13A). There was no significant change after heating between the two treatments 
(increase of 1326±114% after BQ123 and 1459±215% after dual blockade). 
TcPO2 increased significantly during the administration of BQ123+BQ788 (Figure 13B) but 
administration of BQ123 had no effect.
Figure 12. Endothelium-dependent vasodilatation (A–C) and endothelium-independent 
vasodilatation (D–F) determined as change in forearm blood flow (FBF) induced by se-
rotonin and SNP, respectively. A and D: Before and during infusion of BQ123. B and E: 
Before and during infusion of BQ123 + BQ788. C and F: Change from baseline comparing 
the effect of the two treatments. Data are given as means and SEM.
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Biochemical analyses
The baseline values of blood analyses are shown in Table 2. Arterial plasma ET-1 increased 
after administration of BQ123+BQ788 from 0.96±0.14 to 1.75±0.27 pg/mL  (P<0.01) 
whereas it was not changed by administration of BQ123 alone, 0.96±0.18 to 1.1±0.18 pg/mL.
Study III
Study subjects
The subjects of study III are the same as in study I.
Higher body mass index (BMI) and increased waist circumference associated with increased 
ET-1 and higher blood pressure
The baseline characteristics of the 36 subjects are summarized in Table 4. Baseline plasma 
ET-1 levels were 1.61 ±0.83 pg/mL. The cohort was divided into two groups based on the 
median (1.29 pg/mL) in order to compare the association between ET-1 levels on EPC and 
markers of endothelial damage. The groups with high and low ET-1 levels were well matched 
for age, gender and medication.  Patients with high ET-1 levels had increased body mass 
index (BMI), larger waist circumference and had higher systolic blood pressure than those 
with low ET-1 levels. Other important risk factors for cardiovascular disease were similar 
in the two groups. Medication was similar in the two groups except for a higher proportion 
of patients treated with angiotensin receptor blockers (ARB) among those with high ET-1 
levels.
 
Plasma ET-1 is related to EPC levels
Patients with higher levels of ET-1 had higher levels of CD34+CD133+ and CD34+KDR+ 
EPC (Figure 14). In contrast, there was no difference in CD34+ and CD34+CD133+KDR+ 
cells between patients with high and low ET-1 levels. There was no difference in the relative 
number of cells with markers of apoptosis between patients with high and low levels of ET-1 
Figure 13. (A) Cutaneous microvascular flow and (B) Transcutaneous O2 tension at 
baseline and after infusion of BQ123 and BQ123 + BQ788, respectively. Data are given 
as means and SEM. *P<0.05.
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(22 ± 9% vs. 24 ± 15%). Furthermore, there was no difference in circulating levels of ICAM-
1 (224.1 ± 48.0 ng/mL vs. 254.6 ± 77.1 ng/mL) or vWF (1.38 ± 0.62 kIE/L vs. 1.38 ± 0.76 
kIE/L) between patients with high and low ET-1 levels.
Table 4. Baseline characteristics of the study population. Patients were divided according 
to their ET-1 level. The p-value indicates the comparison of the two latter groups. Ns: not 
significant.
Total Study 
Population
Patients with 
ET-1 below 
median 
Patients with 
ET-1 above 
median
p-value
N 36 18 18
Demographics
Age (years) 63.5 ± 7.7 62.4 ± 9.6 64.5 ± 5.3 ns
Gender (male / female) 29 / 7 15 / 3 14 / 4 ns
Height (cm) 175.8 ± 8.4 175.6 ± 6.4 176.2 ± 11.0 ns
Body weight (kg) 96.2 ± 17.1 91.2 ± 16.4 101.6 ± 16.6 ns
Body mass index (kg/m²) 31.2 ± 4.0 29.7 ± 3.4 33.5 ± 3.9 0.012
Waist circumference (cm) 110.5 ± 12.1 106.0 ± 12.4 114.8 ± 10.4 0.032
Blood pressure and heart rate
Systolic blood pressure 
(mmHg) 149 ± 26 139 ± 25 159 ± 24 0.017
Diastolic blood pressure 
(mmHg) 79 ± 10 76 ± 11 80 ± 8 ns
Heart rate (1/min) 66 ± 8 66 ± 7 65 ± 8 ns
Risk factors and comorbidities n (%)
Arterial Hypertension 32 (89%) 14 (78%) 18 (100%) ns
Coronary artery disease 12 (33%) 7 (39%) 5 (28%) ns
Smoking (yes and former) 18 (50) 9 (50%) 9 (50%) ns
Hyperlipidemia 28 (78%) 13 (72%) 15 (83%) ns
Medication n (%)
Statin 22 (61%) 10 (56%) 12 (67%) ns
ACE inhibitor 22 (61%) 12 (67%) 10 (56%) ns
ARB 15 (42%) 4 (22%) 11 (61%) 0.041
Insulin 27 (75%) 12 (67%) 15 (83%) ns
Metformin 19 (53%) 9 (50%) 10 (56%) ns
Laboratory values
LDL (mmol/l) 2.1 ± 0.7 2.0 ± 0.5 2.2 ± 0.8 ns
HbA1c (%) 6.8 ± 1.3 6.5 ± 1.0 7.1 ± 1.5 ns
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Patients with high ET-1 levels had higher CRP levels (3.2 ±2.2 mg/L versus 1.4 ±1.2 mg/L; 
p<0.01). Furthermore, ET-1 and CRP correlated significantly to each other (R²=0.562, 
p<0.001).
ET-1 receptor blockade did not alter EPC numbers
A secondary aim of the third study was to test the effect of dual ETA/ETB receptor blockade on 
EPC and markers of endothelial damage. As described in study I, patients were randomized to 
receive either bosentan or placebo for 4 weeks. Patient characteristics are shown in Table 1.
There was no effect of bosentan treatment on EPC counts either in comparison with baseline 
or with placebo after four weeks of treatment (Figure 15). In addition, there was no signifi-
cant effect on the expression of markers of apoptosis in either treatment arm (25 ± 14% at 
baseline vs. 29 ± 17% at follow-up in the placebo group and 20 ± 10% at baseline vs. 20 ± 
11% at follow-up in the bosentan group).
High ET-1 corresponded to higher CRP levels 
Patients with high ET-1 levels had higher CRP levels (3.2 ±2.2 mg/l versus 1.4 ±1.2 mg/l; 
p=0.008). Furthermore, ET-1 and CRP correlated significantly to each other (R²=0.562, 
P<0.001). 
Figure 14. Different EPC subpopulations compared between patients with ET-1 levels be-
low versus above the ET-1 median. *p < 0.05.
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Biochemichal analyses
Treatment did not have any effect circulating levels of ICAM-1 and vWF. ICAM-1 was 
263.5 ±80.5 ng/mL in the placebo group following treatment (-6.2 ng/ml change from base-
line) and 230.6 ±65.4 ng/mL in the bosentan group following treatment (-3.4 ng/mL com-
pared to baseline). The corresponding values for vWF were 1.50 ±0.80 kIE/L in the placebo 
group following treatment (-0.02 kIE/L compared to baseline) and 1.24 ±0.38 kIE/L in the 
bosentan group following treatment (-0.08 kIE/L compared to baseline). Similarly, there was 
no treatment effect on CRP levels (data not shown).
Figure 15. Different EPC subpopulations compared between patients receiving bosentan or 
placebo for four weeks before initiation of the treatment and after treatment. No significant 
differences or changes could be observed.
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Study IV
Study subjects
The baseline characteristics for the BiKE database have been described in detail by Razuvaev 
et al [106].
ARG2 and EDNRA are downregulated in human carotid artery plaques
Using two non-overlapping BiKE microarray datasets we determined the mRNA levels of genes 
of interest in human plaques (Figure 16A and B). The larger ‘discovery’ dataset comprised 127 
carotid plaques and 10 normal arteries. The smaller ‘validation’ dataset comprised 50 plaques 
and 5 normal arteries. Several genes of interest showed significant differences in expression 
levels comparing plaques vs. normal arteries in the discovery dataset (Figure 16A), and 
this could be further validated in the smaller dataset. In particular, the expression of ARG2 
and EDRNA was strongly down-regulated in plaques (Figure 16A and B) (ARG2 log mean 
difference±SD=-0.40 ± 0.50, p<0.05, EDNRA log mean difference±SD=-2.30 ± 0.81, p<0.01). 
Genes associated with the ET-1/Arg system show dysregulation depending on symptoms of 
atherosclerosis
Next, patients from the discovery dataset were stratified based on clinical symptoms of stroke, 
TIA or amaurosis fugax prior to surgery as symptomatic (n=87) or asymptomatic (n=40). 
Interrogation for expression of genes of interest revealed that EDN1 and EDNRB were significantly 
upregulated in plaques from symptomatic patients (EDN1 log mean difference±SD=0.12 ± 
0.27, p<0.05, EDNRB log mean difference±SD=0.45 ± 0.81, p<0.01) (Figure 16C). Gene 
expression was also determined in PBMCs isolated from symptomatic and asymptomatic 
patients. In this analysis, ARG1, ARG2, EDNRA and EDNRB were all upregulated in PBMCs 
from symptomatic patients (ARG1 log mean difference±SD=0.11±0.17, p=0.0005; ARG2 
log mean difference±SD=0.29±0.58, p<0.05; EDNRA log mean difference±SD=1.56±0.94, 
p<0.001; ETB log mean difference±SD=1.53±1.06, p<0.001; respectively) (Figure 16D). 
Figure 16. Upper row: Gene expression in normal arteries (white bars) and carotid atherosclerotic 
plaques (black bars) using (A) the discovery dataset and (B) the validation dataset. Lower row: 
Gene expression in (C) carotid atherosclerotic plaques and (D) peripheral blood monocytes 
obtained from asymptomatic (white bars) and symptomatic patients (black bars). Data are 
expressed as log2 with SD; *p<0.05, **p<0.01 and ***p<0.001. Abbreviations: ARG=arginase, 
EDN1=endothelin-1, EDNRA=endothelin receptor A, EDNRB=endothelin receptor B.
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Of note, we also observed that ARG1 mRNA displayed overall lower expression levels in 
both plaque tissue and PBMCs in comparison with ARG2. 
Plaque localization of the ET-1/Arg system
To begin to delineate the localization of the ET-1/Arg system in plaques, mRNA expression 
levels for genes of interest from microarrays were first correlated to the levels of typical cell-
specific markers and main processes in plaques. ARG2 expression was significantly correlated 
with several markers of SMCs, macrophages and inflammation (Table 5). In addition, ARG2 
expression was significantly correlated with the expression of the EDNRB receptor. 
Next protein levels and localization of the ET-1/arginase system were determined in 
individual endarterectomies by immunohistochemistry with antibodies against cell-specific 
markers (Figure 17). We observed widespread immunoreactivity for Arg1, Arg2, ET-1 as 
well as its receptors ETA and ETB in plaques. These proteins were all strongly expressed in 
the necrotic core, co-localizing with the macrophage markers CD163 and CD68. In addition, 
Arg2, ET-1 and ETB receptors were also localized in vWF positive endothelial cells as well as 
in SMCs in the fibrous cap and remains of the media at the periphery of the plaque sections. 
Arg1 was detectable but mostly confined to the macrophage-rich areas and only weakly 
Table 5. Correlations between expression of ARG2 and markers of cells/processes in carotid 
atherosclerotic plaques from BiKE microarrays. 
Abbreviations: PECAM-1=platelet endothelial cell adhesion molecule-1,RANK= 
Receptor activator of nuclear factor kappa-Β, CD163=cluster of differentiation 163, IL1 ß 
=interleukin 1 ß, HIF1α =hypoxia-inducible factor1α, ET-1=endothelin-1, ETA= endothelin 
receptor A, ETB=endothelin receptor B, ECE1=endothelin converting enzyme, NOS=nitric 
oxide synthase, ARG=arginase. 
Protein marker Gene Symbol Spearman  r P
Smooth muscle cells
Smoothelin SMTN -0.3767 < 0.001
alpha smooth muscle actin ACTA2 -0.3385 <0.001
Endothelial cells
PECAM-1 (CD31) PECAM1 0.3351 <0.001
von Willebrand factor VWF 0.02935 0.74
Macrophages
RANK TNFRSF11A 0.4678 < 0.001
CD163 CD163 0.4072 < 0.001
Inflammation
IL1ß IL1B 0.4327 < 0.001
HIF 1α HIF1A 0.6088 < 0.001
Endothelin/NO/Arginase pathway
ET-1 EDN1 -0.1137 0.20
ETA EDNRA 0.1416 0.11
ETB EDNRB 0.3614 < 0.001
ECE1 ECE1 -0.01743 0.84
NOS1 NOS1 -0.16 0.07
NOS2 NOS2 -0.2309 <0.01
NOS3 NOS3 -0.0188 0.83
ARG1 ARG1 -0.02952 0.74
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Figure 17. Double stainings of carotid atherosclerotic plaques by immunohistochemistry 
showing co-localisation of selected proteins. Abbreviations: Arg=arginase, ET-
1=endothelin-1, ETA=endothelin receptor A, ETB=endothelin receptor B, vWF=von 
Willebrand factor, SMA=smooth muscle actin.
present in other cell types. ET-1 and the ETA and ETB receptors were co-localized with both 
isoforms of arginase in cells of the necrotic core, identified by the macrophage marker CD68 
and sporadically also by alpha-smooth muscle cell actin (SMA).
ET-1 stimulates arginase activity and ROS production
Based on the co-localization of ET-1 and arginase in the atherosclerotic plaque, we investigated 
the functional interactions between the two in vitro. Human carotid endothelial cells (ECs) 
were stimulated with ET-1 and the expression of ARG1 and ARG2 was determined. ET-1 
induced a rapid increase in ARG2 mRNA expression already after 2 h of stimulation (Figure 
18A) and this was accompanied by a 3-fold increase in arginase activity at 4 and 24 h (Figure 
18B). In contrast, ARG1 expression in ECs and THP-1 derived macrophages was consistently 
low and did not change in response to ET-1. 
ET-1 also induced a significant increase in arginase activity in THP-1 derived macrophages 
although the mRNA expression of ARG2 was not significantly increased (Figure 19A and B). 
The increase in arginase activity was blocked by macitentan and the selective ETB receptor 
antagonist BQ788 (Figure 19B). The functional consequence of the increase in arginase 
activity by ET-1 stimulation was investigated by determination of ROS formation. Incubation 
of THP-1 derived macrophages with ET-1 increased ROS production by 30% (Figure 19C). 
The effect was completely blocked by the arginase inhibitor ABH.
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Figure 18. (A) Endothelial cell ARG2 mRNA expression and (B) arginase activity under 
control conditions and following stimulation with ET-1(1 nM, n=8) in the absence and pres-
ence of the dual ET receptor antagonist macitentan (10 µM, n=7). Data are given as mean and 
SEM and presented as relative change compared to control; **p<0.01, ***p<0.001 indicate 
significant changes over time, and #p<0.05 indicates significant difference vs. ET-1 24h.
Figure 19. (A) ARG2 mRNA expression and (B) arginase activity in THP-1 macrophages 
under control conditions and following stimulation with ET-1 (1 nM, n=8) in the absence 
and presence of the dual ET receptor antagonist macitentan (10 µM, n=7) or the ETB recep-
tor antagonist BQ788 (1 µM, n=7). (C) Production of reactive oxygen species by THP-1 
cells under control conditions and following stimulation with ET-1 in the absence and pres-
ence of the arginase inhibitor ABH (1 mM, n=4). Data are given as mean and SEM and 
presented as relative change compared to control (A-B) or in absolute values (C); *p<0.05 
indicate significant differences between groups.
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DISCUSSION
Atherosclerosis is an enormous healthcare burden with high mortality and morbidity 
throughout the entire world. Endothelial dysfunction is thought to be the first step towards 
atherosclerosis and is also considered to be an integral part of the development of vascular 
complications in diabetes [14, 15]. Defined as decreased bioavailability of NO, endothelial 
dysfunction is probably the result of many different processes among which both ET-1 and 
arginase play important roles [59, 94]. This thesis explores these interactions utilizing several 
research methods; ranging from the cell, to the patient to a cohort of patients.
Effects of ET-1 blockade on endothelial function in patients with type 2 
diabetes
Several studies have indicated that ET-1 plays a role in the development of vascular 
complications in diabetes. ET-1 levels are known to be higher in patients with diabetes mellitus 
[35] and endothelial function improves following acute intra-arterial administration of ET 
receptor blockers in patients with glucometabolic perturbations and manifest T2D [43, 107, 
108] with or without manifestations of coronary artery disease. However, no previous study 
had addressed the question whether long-term oral administration of an ET receptor blocker 
improves endothelial function in patients with T2D and established vascular complications.
The first study of this thesis therefore examined patients with T2D and microalbuminuria, 
who were randomly adminstered the oral endothelin receptor blocker bosentan or placebo. 
The results demonstrated that 4 weeks treatment with bosentan significantly improved digital 
microvascular function measured with the PAT signal compared to baseline and compared 
to placebo. These findings are relevant as previous studies have shown that a large part of 
the Endo-PAT signal during reactive hyperemia is dependent on NO availability [109, 110] 
and decreased RHI has been shown to be an independent risk factor for the development of 
cardiovascular events [91]. There was no change in brachial artery FMD which was measured 
simultaneously with the Endo-PAT. Previous studies have indicated that PAT and FMD 
provide distinct information regarding vascular function in smaller digital vessels vs. conduit 
arteries [111]. The results show that bosentan improves endothelial function in small vessels 
rather than the larger conduit arteries within the timeframe of the study. This is of particular 
interest in patients with T2D as they develop early disturbance in microvascular endothelial 
function [112]. Microvascular dysfunction in this patient category has been implicated in 
increased risk for cardiovascular outcomes [113].
These results indicate that ET receptor blockade may provide a beneficial therapeutic strategy 
to reverse microvascular dysfunction in T2D. A possible treatment effect associated with this 
outcome is a lower urine albumin/creatinine ratio. In this study we observed a non-significant 
trend towards a lowering of this ratio which is supported by a larger trial in which a reduction 
in urine albumin/creatinine ratio was observed in patients with diabetic nephropathy treated 
with the selective ETA receptor blocker atrasentan [114]. 
The choice of ET receptor blocker is perhaps dependent on what condition is under 
consideration. Fluid retention is an issue with ET-1 receptor blocking. When the ETA receptor 
is selectively blocked the renin angiotensin system is upregulated [115] with resulting fluid 
accumulation. When both receptors are blocked urine volume is reduced through an ETB 
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receptor mediated mechanism in the kidneys [116]. Normally, the ETA receptor is found in the 
smooth muscle cells of the vessel wall mediating vasoconstriction whereas the ETB receptor is 
mostly found in the endothelial cells mediating vasodilatation and a smaller fraction present 
in smooth muscle cells mediating vasoconstriction. The net effect of ET-1 thus depends on 
the receptor localization and the balance of ETA and ETB receptors. Stimulation of the ETA 
receptor causes vasoconstriction and increased oxidative stress, whereas stimulation of the 
ETB receptor may cause vasodilatation in healthy subjects or vasoconstriction in patients with 
atherosclerosis due to upregulation of ETB receptors on smooth muscle cells [24, 26]. Thus, 
the function of the ETB receptor seems to change from stimulating vasodilatation via release 
of NO in healthy vessels to mediating vasoconstriction by activating receptors located on 
vascular smooth muscle cells in atherosclerosis.
The ETB receptor is also upregulated on macrophages that are resident in the atherosclerotic 
plaque [29, 117] and in both macrophages and smooth muscle cells exposed to oxidized LDL 
[118]. An experimental study on mice demonstrated a marked reduction in atherosclerotic 
plaque formation when treated with a dual ET receptor blocker [119]. Unfortunately, the effect 
of selective ETA inhibitor was not investigated in that study. Selective ETA receptor blockade 
has been shown to increase coronary endothelial function in patients with atherosclerosis 
[44]. In another study selective ETA receptor blockade improved microvascular nutritive 
capillary function in patients with T2D [43]. In a study including patients with insulin 
resistance and without known coronary heart disease only dual receptor inhibition showed 
improved endothelial function [107].
Collectively, available data suggest that both selective ETA receptor blockade and dual ETA/
ETB receptor blockade may improve endothelial function in the setting of T2D and CAD. 
However, a direct comparison has to date not been performed. This led to the design of 
study II in which the effect of selective ETA receptor blockade vs. dual receptor blockade on 
ED was investigated in patients with T2D and manifest CAD. This is the first study where 
selective ETA and dual ETA/ETB receptor blockers are compared in this setting in humans.
The main finding was that selective ETA and dual ETA/ETB receptor blockade seemed to be 
equally effective. Both led to a marked increase in endothelium-dependent and endothelium-
independent vasodilatation and there was no negative effect from blocking the ETB receptor, 
perhaps owing to the changed role the receptor has in advanced vascular disease. The ETB 
receptor is not only upregulated in the smooth muscle cells of the atherosclerotic plaque 
but also in the macrophages implying a possible role in generation of ROS. ROS in foamy 
macrophages have been linked to increased matrix metalloproteinase activity resulting 
in instability of the plaque [120]. Furthermore, this corrupted role of the ETB receptor in 
individuals with vascular disease has been supported in a study of rats with pulmonary 
hypertension where the blood pressure drop was significantly larger in the group that 
received macitentan, a dual ETA/ETB receptor blocker, in addition to ambrisentan, an ETA 
receptor blocker compared to ambrisentan alone. Conversely, when ambrisentan was added 
to macitentan vs macitentan alone there was no additional effect [121]. The increase in 
endothelium-independent vasodilatation has been shown in previous studies using ET 
receptor blockade and other interventions aiming at increasing NO bioavailability. In these 
studies endothelium-dependent and endothelium-independent vasodilatation increased in 
patients with T2D but not in patients without the disease [63, 107, 122]. 
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Dual ETA/ETB blockade increased basal blood flow as well as the TcPO2. Selective ETA 
blockade on the other hand increased laser Doppler flow which might benefit wound healing, 
but available evidence is not convincing. The reason for the difference  between the effects 
of the treatments are unclear. Laser Doppler measures total flow in the skin below the probe, 
both arterial and venous whereas TcPO2 measures oxygen content in the skin. The response 
to ET-1 in the smaller vessels seems to be mainly dependent on ETA and less so on the ETB 
receptor [123]. In these smallest vessels, the vasodilatory response of ETB receptor might still 
be significant and thus dual blockade not as effective. The increase in the TcPO2 with dual 
blockade might indicate a potential target population of patients with diabetic foot ulcers. In 
a recent meta-analysis TcPO2   was a reliable predictor of the healing of foot ulcers in diabetic 
patients as well as predicting risk of future amputations [124]. 
Effects of inflammation on EPC numbers in patients with T2D 
Several different pathological conditions including atherosclerosis, diabetes, hyperlipidemia 
and hypertension lead to a reduced number of EPC [125]. Possible mechanisms could be 
exhaustion of the pool of progenitor cells in the bone marrow, impaired functional capacity 
within the bone marrow, reduced mobilization of EPC, or reduced survival and/or differentia-
tion of mobilized EPC [126].
In contrast to the above there are a number of studies involving physiological and pathological 
stimuli that increase EPC levels. The factors that recruit EPC are insulin-like growth 
factor-1, growth hormone, GCSF, VEGF and stromal-derived factor-1 [127, 128]. Vascular 
inflammation has also been linked to increased EPC numbers. In a study from 2004, CRP 
levels correlated to EPC in patients with unstable angina [129]. Another study, involving 
exogenous vascular injury, linked increased EPC numbers with local vascular inflammation 
[130].
The main findings in study III were that in patients with T2D and vascular disease, high 
levels of ET-1 were associated with a higher number of EPC. Patients with higher ET-1 levels 
also had a higher CRP as well as higher systolic blood pressure, thus supporting the view that 
vascular inflammation triggers the recruitment of EPC. It has been shown in previous work 
that ET-1 is associated with hypertension and vascular inflammation [131].
Higher ET-1 levels were also associated with increased waist circumference in the present 
study, supporting previous work that indicated that being overweight, in the absence of acute 
vascular events, is associated with vascular inflammation as well as with increased EPC 
numbers [132]. 
In the present study there was no effect on the number or viability of EPC with oral ETA/ETB 
receptor blockade with bosentan. This observation suggests that recruitment of EPC does not 
seem to be regulated by ET-1 via a receptor-dependent mechanism. Other pharmacological 
compounds have been linked to beneficial effects on the number and function of EPC [133]. 
Few of these studies were randomized, but statins [134], angiotensin II receptor antagonists 
[135] and pioglitazone [136] have been shown to positively affect EPC in placebo-controlled 
randomized studies. 
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Together these observations support the theory that vascular inflammation is associated with 
increased levels of ET-1 and EPC. In this context it is important to note that only circulating 
EPC counts have been investigated. Earlier studies have shown the positive association 
between inflammation and the number of circulating EPC, but it has also been shown by 
different investigators that inflammation impairs EPC function [137]. Although the results 
were negative it might have been because the treatment time was only four weeks, a longer 
time period could be necessary to allow for the inflammation to decrease. Another possibility 
is that even though EPC numbers did not increase, their function might have improved. 
 
ET-1 and arginase in human atherosclerotic plaques
Both ET-1 and arginase exert pro-inflammatory effects in the cardiovascular system and 
promote the development of atherosclerosis [31, 58]. Both reduce the bioavailability of NO 
and their expression is increased by risk factors for atherosclerosis. Although extensively 
studied by various groups, a possible connection between the two has never been established. 
Because NO bioavailability is similarily affected by ET-1 and arginase, it has been speculated 
that effects of ET-1 are dependent on arginase. Utilizing expression data from a unique biobank 
of human carotid atherosclerotic plaques, the approach encompassed an integrative analysis 
of members of the ET and arginase families. In our analysis we found that ET-1 along with its 
receptors, ETA and ETB and arginase, especially Arg2, were abundantly expressed in human 
atherosclerotic plaques. Both ET-1 and Arg2 were expressed in macrophages and endothelial 
cells as well as those smooth muscle cells associated with the fibrous cap. These observations 
support the notion that ET-1 and Arg2 may be of importance for plaque development and 
instability. The presence of ET-1 and arginase has previously been identified in atherosclerotic 
lesions [138, 139] but this is the first time they have been demonstrated to co-localize in 
human atherosclerosis.
 
The driving forces of atherosclerosis are the dysfunction of endothelial cells followed by an 
influx of monocytes that later turn into macrophages. The regulation of endothelial cells and 
macrophages is dependent on NO production and the counter-acting effects of arginase. Both 
have receptors for ET-1. Study IV demonstrated the presence of ET-1 and arginase in plaque 
areas dense with macrophages and in the endothelium. The functional interactions between 
ET-1 and arginase were investigated in vitro. Interestingly, ET-1 induced upregulation of 
ARG2 expression and arginase activity in endothelial cells and increased arginase activity in 
THP-1-derived macrophages. To the best of our knowledge, this is the first demonstration of 
a regulatory effect of ET-1 on arginase expression and activity.
The stimulatory effect of ET-1 on arginase in endothelial cells is of interest considering the 
ability of ET-1 to reduce the bioavailability of endothelial NO and endothelium-dependent 
vasodilatation in patients with coronary atherosclerosis [140]. Arginase is known to be a 
critical regulator of NO production due to competition for the substrate L-arginine in 
endothelial cells [66]. Thus, the present findings indicate that increased arginase activity is an 
important mechanism by which ET-1 induces endothelial dysfunction. The importance of the 
interaction between ET-1 and arginase for endothelial cell and NO production is of interest 
to explore further in future studies. 
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In addition, THP-1-derived macrophages responded to ET-1 stimulation by increasing 
arginase activity as well as increased ROS production. No significant ARG1 expression was 
detected after stimulation of THP-1 derived macrophages in this experiment, while ARG2 
expression was clearly present but not increased in a statistically meaningful way. Induction 
of Arg2 has been reported to reflect a polarization towards the pro-inflammatory subtype 
macrophage, M1 [141], while Arg1 has been associated with M2, the anti-inflammatory 
subtype [142]. However, the functional role of arginase in macrophages is complex and still 
elusive.
Arginase has previously been implicated in ROS production, which has been shown to take 
place in the mitochondria of macrophages [143]. Interestingly, it has been suggested that 
Arg2 promotes the pro-inflammatory responses of macrophages through mitochondrial 
ROS contributing to plaque formation [141]. Inhibiting Arg2 may thus represent a potential 
therapeutic strategy in atherosclerosis, especially as there is evidence that macrophages retain 
their plasticity after differentiation to one subtype [142]. 
Study IV provided clear evidence for an upregulation of ET-1 and ETB receptor in carotid 
plaques from symptomatic patients. Furthermore, PBMCs of patients with recent symptoms 
had increased expression of the ETB and ETA receptors. Monocytes are paramount in 
atherogenesis and their influx into the artery wall and subsequent development into 
macrophages is vital for plaque formation [144]. The increase in ETB receptor expression 
in plaques from symptomatic patients is in line with the previous observation of a change 
in the function of the ETB receptor in atherosclerosis. Thus, the ETB receptor contributes to 
vasoconstrictor tone and endothelial dysfunction in patients with atherosclerosis [26, 145, 
146]. The connection to a more acute presentation of atherosclerosis implies an enhanced 
role of ET-1 and especially the ETB receptor. 
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PERSPECTIVE
Taken together, the evidence points towards an enhanced role of ET-1 in the unstable 
plaque via the ETB receptor in the proatherogenic environment. The clinical studies I and 
II indicate that blocking both the ETA and ETB receptors in patients with manifest vascular 
disease improves endothelial function. Compared to selective ETA blockade, dual blockade 
increased skin oxygenation and is a possible treatment for chronic ulcers in patients with T2D 
as was suggested in a case report [147]. Study IV also implies that ET-1 has a role in plaque 
instability via increased production of ROS through Arg2. It also shows a possible link to the 
immune system as seen in the increased expression of both ET-1 and ETB receptor in PBMC. 
If we try to follow events in a possible scenario of atherosclerosis, risk factors increase 
the amount of ET-1 that causes an influx of primed monocytes into the vessel wall through 
the dysfunctional endothelium. On site the monocyte is influenced into the M1 phenotype 
through an Arg2 dependent pathway. The results indicate that both ET-1 and Arg2 are more 
involved in carotid plaques from symptomatic patients. As study IV showed, there is an 
increase in ETB receptor in the plaque tissue of patients with more recent symptoms. It also 
showed that macrophages, when stimulated with ET-1, increased their ROS production. This 
increased ROS production has been shown to promote plaque instability [120]. Together with 
the results of the first and second studies this points toward an enhanced role of ET-1 and ETB 
receptor in patients with diabetes and vascular disease. 
The big question is whether there is a real therapeutic opportunity in either the ET-1 receptor 
blockers or an arginase inhibitor? Both systems are widespread throughout the body and 
thus a variety of different side-effects are possible. ET-1 receptor blockers are already 
established treatments for a limited number of disease states such as pulmonary vascular 
hypertension [148] and vascular complications of scleroderma [149]. In addition there is an 
ongoing trial aiming to determine wether the selective ETA blocker atrasentan can reduce 
the risk of progression and delay the onset of end-stage renal disease in patients with T2D 
and nephropathy [150].
Studies with arginase inhibitors have shown promising results in human subjects. Intra-arterial 
infusion of nor-NOHA, an arginase inhibitor, improved endothelial function in patients with 
coronary artery disease with and without T2D [66]. Furthermore, arginase inhibition improved 
cutaneous microvascular function in patients with T2D and microvascular complications 
[151]. Other studies demonstrated improvement in endothelial function in patients with 
hyperlipidemia [152, 153]. Collectively, these observations indicate that arginase inhibition 
may be beneficial in human cardiovascular disease and T2D.
As a best case scenario the therapies would target the unstable atherosclerotic lesion. This 
treatment, in addition to traditional risk factor management and a healthier lifestyle, has 
the promise of reducing the incidence of the most severe manifestations of atherosclerotic 
disease.
Closer in the future is the possibility of shortening wound healing time in patients with 
diabetes foot ulcers using a dual ETA/ETB receptor blocker, a class of drugs already in use 
[149]. The ever increasing group of patients with T2D presents modern healthcare with a 
deluge of wounds needing costly long term management.
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An important point to consider regarding drug therapies are side effects. ET-1 blockers are 
already in use with established side effects that include fluid retention, edema, increase in 
liver transaminases, headaches and facial flushing [154]. Arginase inhibitors are still in 
experimental phase. In these small trials the inhibitors seem to be well tolerated but larger 
studies are needed for a full profile of side effects [152]. A possible cause of concern is the 
disruption of the hepatic urea cycle which is vital for the individual. A number of different 
inhibitors have been developed but none are selective for either type of the enzyme [155]. 
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LIMITATIONS
The studies of this thesis have several limitations, including a lack of female participants, 
study size, study duration and control factors.
In spite of efforts, the number of female participants in the studies is low. There seem to 
be gender differences in the contribution of the ETB receptor in cutaneous vascular tone 
of healthy individuals [156]. Middle aged men seemed to have an increased ETA mediated 
vasoconstrictor tone compared to women [157] although vasoconstrictor response to ET-1 
was similar between the sexes. A possible cause is estrogen, as estrogen replacement therapy 
was shown to decrease the circulating levels of ET-1 in a study of postmenopausal women 
[158].
In studies I and III the same cohort was used and the sample size was small. Owing to 
technical issues the final number of samples available for analysis in study III was even 
smaller. Another possible weakness is the study duration. Four weeks is possibly too short 
to make a significant impact on a chronic disease like T2D and perhaps the reason that 
improvement was only detected in microvascular function and not macrovascular function.
Blood pressure decreased significantly in the treatment group compared to the control group. 
Tailoring a study where blood pressure reduction in the control group is the same, using a 
drug without vasoactive properties, is complicated.  
In study II the number of patients is arguably low but there is no indication that a larger group 
would have changed the outcome as the effect was similar to the prediction in the power 
calculation.  
In study IV the number of healthy arteries used as controls is low and from another anatomical 
location than the diseased carotid plaques. For in vitro studies, macrophages obtained by 
differentiating THP-1 cells were used, which is an immortalized monocyte-like cell line and 
not ex vivo obtained monocytes from individuals.  
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CONCLUSIONS
I.  Four weeks oral treatment with the dual ETA/ETB receptor blocker bosentan improved 
peripheral microvascular endothelial function in patients with type 2 diabetes and 
microalbuminuria.
II.  Both selective ETA dual ETA/ETB receptor blockade markedly improved endothelial 
function in patients with coronary artery disease and type 2 diabetes. 
III.  ET-1 and Arg2 are co-expressed in human atherosclerotic plaques. ET-1 stimulated Arg2 
expression and activity in endothelial cells as well as ROS formation in macrophages 
via an arginase-dependent mechanism. These results indicate an important interaction 
between the ET pathway and arginase in human atherosclerotic plaques.
IV.  Among patients with type 2 diabetes and vascular disease, high levels of ET-1 are 
associated with higher numbers of EPC. The recruitment of EPC does not seem to 
be regulated by ET-1 receptor activation since treatment with a dual ET-1 receptor 
blocker did not affect circulating EPC numbers.
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OVERALL SUMMARY AND CONCLUSION
Long term ETA/ETB receptor blockade improved the microvascular function in patients 
with T2D and CAD. Adding ETB on top of selective ETA blocker did not seem to improve 
endothelium-dependent vasodilatation although a small but significant effect was seen on 
tissue oxygenation compared to selective ETA blockade. These effects might have therapeutic 
implications when it comes to treatment of diabetic microvascular complications. As 
illustrated in Figure 20, ET-1 has an integral part in the development of atherosclerosis and the 
progression of diabetic complications. Part of the effect might be through increased arginase 
expression and activity. This may indicate possible future targets in treating or hindering the 
progression of atherosclerotic disease. 
Figure 20. Schematic illustration of the roles of ET-1 and arginase and their interplay in 
endothelial cells and macrophages. ET-1 is upregulated by traditional risk factors. In ad-
dition, ETB receptors are increased in vascular smooth muscle cells and on macrophages 
which contributes to increased vascular tone, impaired endothelial function and oxidative 
stress. ET-1 stimulates Arg2 expression and activity in endothelial cells as well as ROS 
formation in macrophages via an arginase-dependent mechanism. ET-1= endothelin 1, 
ETA=endothelin receptor A, ETB= endothelin receptor B, eNOS= endothelial nitric oxide 
synthase, NO= nitric oxide; ONOO−=peroxynitrite, ROS= reactive oxygen species. 
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